Artículos de revistas sobre el tema "822/.009 b"
Siga este enlace para ver otros tipos de publicaciones sobre el tema: 822/.009 b.
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "822/.009 b".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
1
Marcucci, Guido, K. Mrózek, A. S. Ruppert, K. Maharry, J. E. Kolitz, R. J. Mayer, M. J. Pettenati et al. "t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study." Blood 104, n.º 11 (16 de noviembre de 2004): 2017. http://dx.doi.org/10.1182/blood.v104.11.2017.2017.
Texto completoResumen
Abstract Since t(8;21) and inv(16) disrupt core binding factor in AML and confer a favorable prognosis, these cytogenetic groups are often treated similarly, but hitherto have not been compared in a large study. We compared 144 adult AML patients (pts) with t(8;21) with 168 with inv(16) enrolled on the cytogenetic study CALGB 8461. t(8;21) pts were less frequently white (P=.01), had lower hemoglobin levels (P=.03), WBC (P<.001) and % blood (P<.001) and BM blasts (P=.005), and had more frequently secondary chromosome aberrations (P<.001) than inv(16) pts, who more often had extramedullary disease (P<.001). Pts were induced with cytarabine/daunorubicin (AD) or cytarabine/daunorubicin/etoposide ±PSC833(ADE±P). Complete remission (CR) was achieved by 89% of t(8;21) and 87% of inv(16) pts. Upon multivariable analysis (MVA), non-white race (P=.006), lower platelets (P=.01) and higher BM blasts (P=.004) predicted negatively for CR in t(8;21), and lower platelets (P=.009) and hepatomegaly (P=.04) in inv(16) pts. Non-whites with t(8;21) had 5.7 times the odds of not achieving CR as whites. For the entire group (median follow-up 6.4 yrs), the estimated 5-yr overall survival (OS) and cumulative incidence of relapse (CIR) were 51% and 53%, respectively. Pts with t(8;21) showed a trend for shorter OS (46% vs 54%; P=.17) but no difference in CIR compared with inv(16) pts. Upon MVA, t(8;21) pts had worse OS than inv(16) pts (HR 1.5; P=.04), once adjusting for age, platelets, and WBC. Following first relapse, the 5-yr survival of t(8;21) pts (n=58) was shorter than that of inv(16) pts (n=74) (14% vs 36%; P=.01); in an age-adjusted model, the risk of death was 1.8 times higher for t(8;21) pts (P=.005). In a subanalysis of pts <60 yrs, consolidation therapy with multi-course high-dose cytarabine (HDAC x3 or 4) significantly decreased CIR compared to single-course HDAC (x1) in t(8;21) (5-yr CIR, 35% vs 64%; P=.005) and inv(16) (5-yr CIR, 44% vs 70%; P =.03) pts. Upon MVA, consolidation with multi-course HDAC reduced CIR for both t(8;21) and inv(16), but other prognostic factors differed (see Table). For t(8;21), induction with ADE±P and higher platelets increased risk of relapse. However, relatively few pts received ADE±P so its prognostic impact requires confirmation. For inv(16), +22 and other secondary cytogenetic aberrations, and male sex were favorable prognostic factors. Multivariable analysis (MVA) for CIR in pts <60 yrs achieving CR on CALGB 8221, 8525, 9022, 9222, 9621 Variable t(8;21) HR (95% CI); P inv(16) HR (95% CI); P HR=Hazard Ratio, CI=confidence intervals —, not included in final model Consolidation:Single vs multi-course HDAC 4.5 (2.1-9.4); <.001 3.4 (1.7-6.6); <.001 Induction:ADE±P vs AD 2.6 (1.1-5.9); .02 1.4 (0.6-3.2); .41 log(platelets) 1.8 (1.2-2.9); .007 — Secondary cytogenetics — 0.2 (<0.1-0.5); .002 Male vs Female — 0.5 (0.3-0.9); .03 In summary, once pretreatment factors and therapy are considered, the outcome of t(8;21) AML appears inferior to that of inv(16). Although these data should be confirmed prospectively, our analysis suggests that future studies should report the outcomes of pts with t(8;21) and inv(16) separately, and seek to identify and target therapeutically leukemogenic mechanisms accountable for these clinical differences.
2
Park, Hyunjin, Kyu Hyoung Lee, Minsu Heo, Sang-il Kim y Hyun-Sik Kim. "Strategies for the High Average zT in the Electron-Doped SnTe". International Journal of Energy Research 2023 (15 de diciembre de 2023): 1–14. http://dx.doi.org/10.1155/2023/5512034.
Texto completoResumen
We propose a new strategy to achieve a high average zT in electron-doped SnTe by applying the two-band (TB) and single parabolic band (SPB) models to the electronic transport properties of Sn0.97M0.03Te ( M = Ga , In, Bi, and Sb) reported in the literature. To achieve a high average zT at temperatures from 300 to 823 K, both zT at 300 and 823 K should be high with a steadily increasing zT over the temperatures. The p-type SnTe is known to have a light valence band and a heavy valence band that are approximately 0.40 eV apart. The Bi-doped SnTe exhibits one of the highest zT among all the other doped samples at 300 K (0.09) and the highest zT at 823 K (0.9), with a steadily increasing zT in between. The TB model confirms the presence of the resonant state at 300 K which is responsible for the high zT at 300 K. The B-factor, which is related to the theoretical maximum zT, calculated by the SPB model indicates a steady increase in zT with increasing temperature. The temperature-dependent B-factor of the Bi-doped SnTe suggests that the initial position of its Fermi level at 300 K calculated by the TB model may be responsible for the temperature coefficient of the B-factor, which determines the zT at 823 K. According to the SPB model, experimental zT of 0.9 of the Bi-doped SnTe can be further improved to 1.03 (14% improvement) at 823 K upon carrier concentration optimization. To achieve a high average zT in SnTe, electron doping with a dopant that forms a resonant state and placing the Fermi level at the light valence band in the vicinity of the heavy valence band maximum are both essential.
3
Massey, Heather, Paul Gorczynski, C. Mark Harper, Lisa Sansom, Kieren McEwan, Alla Yankouskaya y Hannah Denton. "Perceived Impact of Outdoor Swimming on Health: Web-Based Survey". Interactive Journal of Medical Research 11, n.º 1 (4 de enero de 2022): e25589. http://dx.doi.org/10.2196/25589.
Texto completoResumen
Background Outdoor swimming in lakes, lidos (outdoor pools), rivers, and the sea has grown in popularity in many countries, including the United Kingdom. Many anecdotal accounts indicate improvements in medical conditions, which are considered a consequence of outdoor swimming. Objective The aim of this study is to better understand outdoor swimmers’ perceptions of their health and the extent to which participation impacted their existing self-reported symptoms. Methods A survey was conducted to investigate outdoor swimming behaviors and reports of any diagnosed medical conditions. Medical conditions were coded into categories, and descriptive statistics were generated regarding the outdoor swimmers’ behaviors and the effect that outdoor swimming had on their medical symptoms if any. The medical categories were clustered into five larger categories based on their prevalence in the current sample: mental health; musculoskeletal and injury; neurological; cardiovascular and blood disease; and other, which comprises inflammatory, immune, endocrine, and respiratory conditions. Results In total, 722 outdoor swimmers responded, of whom 498 (68.9%) were female. The probability of outdoor swimming having some positive impact on health across all medical categories was 3.57 times higher compared with no impact (B=1.28, 95% CI 0.63-1.91; P<.001), 44.32 times higher for the mental health category (B=3.79, 95% CI 2.28-5.30; P<.001), 5.25 times higher for musculoskeletal and injury category (B=1.66, 95% CI 0.52-2.79; P=.004), and 4.02 times higher for the other category (B=1.39, 95% CI 0.27-2.51; P=.02). Overall, outdoor swimming was associated with perceived reductions in symptoms of poor mental health (χ22=25.1; P<.001), musculoskeletal and injury (χ22=8.2; P=.04), cardiovascular and blood (χ22=14.7; P=.006), and other conditions (χ22=18.2; P<.001). Conclusions Physical activity in the form of outdoor swimming is perceived to have positive impacts on health and is associated with perceived symptom reductions in mental health, musculoskeletal and injury, and cardiovascular and blood conditions. This study cannot provide causal relationships or provide mechanistic insights. However, it does provide a starting point for more targeted prospective intervention research into individual conditions or categories of conditions to establish the impact in those who choose to start outdoor swimming.
4
Sumiati, Neneng Tati y Syanindia Annisa Dewi. "The Relationship of Severity Level of Autism and Parent’s Unconditional Love on Children with Autism Moderated by Religiosity and Social Support". Jurnal Psikologi 20, n.º 2 (31 de octubre de 2021): 187–204. http://dx.doi.org/10.14710/jp.20.2.187-204.
Texto completoResumen
Children with autism have difficulties in social interaction, lack of communication, and repetitive behavior. Thoseconditions make parents come to grips with several drawbacks in taking care of their autistic children. Thepurpose of this study was to determine the relationship between the severity level of autism and the unconditionallove of parents, moderated by religiosity and social support. This study was using a quantitative approach withstructural equation model (SEM) analysis. Participants in this study were 200 parents of children with AutismSpectrum Disorder (ASD) aged 2-17 years old and were selected by the non-probability sampling technique. Themeasurements applied in this study were unconditional love scale, taken from Porter Parent Acceptance scale,which consists of four items (α = .802; AVE = .628), social support scale, which consists of three items (α = .703;AVE= .628), Brief Multidimensional Measure of Religiousness/Spirituality, which consists of ten items (α =.952; AVE= .699), and Childhood Autism Rating Scale, which consists of four items (α = .756; AVE= .574). Theresult indicated that the unconditional love of parents was significantly affected by severity level of autism, b = -.162; t(196) = 2.849, p = .005; religiosity, b = .534; t(196) = 7.101, p = .000; and social support, b = .157; t(196)= 2.426, p = .016. Religiosity was proven to be essential in moderating the relationship of severity level of autismand unconditional love, b = .249; t(196) = 3.262, p = .001); while social support was not, b = -.020; t(196) = .293,p = .770. Religiosity could help maintain the unconditional love of parents for their autistic children, while socialsupport was not enough to buffer stress caused by them. Thus, parents of children with autism are urged toincrease their level of religiosity
5
Boekhout, Janet M., Brenda A. J. Berendsen, Denise A. Peels, Catherine A. W. Bolman y Lilian Lechner. "Physical Impairments Disrupt the Association Between Physical Activity and Loneliness: A Longitudinal Study". Journal of Aging and Physical Activity 27, n.º 6 (1 de diciembre de 2019): 787–96. http://dx.doi.org/10.1123/japa.2018-0325.
Texto completoResumen
This study explores the association between physical activity (PA), loneliness, and the presence of physical chronic impairments among single older adults. A longitudinal study (N = 575; mean age 76 ± 8 years) was conducted. The association between self-reported weekly minutes of moderate to vigorous PA, loneliness, and presence of physical impairments was assessed with multilevel analyses at baseline, 3 months, and 6 months. Improvements in moderate to vigorous PA were associated with decreases in loneliness (B = −0.09, SE = 0.04, p = .020); this association became nonsignificant when including the presence of physical impairments in the analyses (p = .824), which in itself was positively associated with loneliness (B = 0.51, SE = 0.10, p < .001). Findings indicate that physical impairments have a larger influence on loneliness than the level of PA. Interventions targeting PA and loneliness should tailor specifically to physical impairments.
6
Lee, Shing Fung, Miguel Angel Luque-Fernandez, Yu Hui Chen, Paul J. Catalano, Chi Leung Chiang, Eric Yuk-Fai Wan, Ian Chi-Kei Wong, Ming Hui Chen y Andrea K. Ng. "Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong". Blood Advances 4, n.º 20 (21 de octubre de 2020): 5107–17. http://dx.doi.org/10.1182/bloodadvances.2020002737.
Texto completoResumen
Abstract Evidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we identified adults who were diagnosed with DLBCL and treated with chemotherapy between 2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric competing risk analysis and adjusting for demographics, comorbidities, therapeutic exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-matched to DLBCL patients. We analyzed 2600 patients and 13 000 controls. The adjusted cause-specific hazard ratio (HR) for CVD in patients treated with >500 mg doxorubicin compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74; P = .013). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%, 4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; P = .082) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline (HR, 2.13-4.63; P < .001 to .002) might confer a higher risk of subsequent CVDs. In this Hong Kong population-based study, doxorubicin exposure (absolute dose >500 mg), together with hypertension or baseline use of medication for cardiovascular risk factors, was found to be associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients are advisable.
7
Battaglin, Francesca, Harris Krause, Andrew Elliot, Jim Abraham, Shivani Soni, Sandra Algaze, Priya Jayachandran et al. "SETD2 gene expression and the molecular landscape of colorectal cancer (CRC)." Journal of Clinical Oncology 41, n.º 4_suppl (1 de febrero de 2023): 184. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.184.
Texto completoResumen
184 Background: SETD2, a key methyltransferase modulating histone 3 gene transcription, has been shown to act as a tumor suppressor gene by reducing oxidative stress, colonic inflammation and tumorigenesis in animal models. SETD2 gene expression has been reported to be significantly downregulated in CRC and linked with poorer patient survival. Additionally, SETD2 plays an important role in DNA repair and loss of function mutations have been associated with increased tumor mutational burden (TMB), mismatch repair (MMR) deficiency, and benefit from immunotherapy. Hence, we aimed to characterize the molecular features associated with SETD2 gene expression in CRC. Methods: 15,425 CRC tumors tested at Caris Life Sciences (Phoenix, AZ) with NextGen Sequencing on DNA (592 genes or whole exome sequencing), RNA (whole transcriptome sequencing), and IHC were analyzed. SETD2-high and -low expression were defined as ≥ top and < bottom quartile of SETD2 transcripts per million (TPM), respectively. Cell infiltration in the tumor microenvironment (TME) was estimated by QuantiSEQ. Mann-Whitney U and X2/Fisher-Exact tests were applied where appropriate, with P-values adjusted for multiple comparisons ( q < .05). Gene expression profiles were analyzed for transcriptional signatures predictive of response to immunotherapy (T cell-inflamed) and MAPK pathway activation (MPAS). Real-world overall survival information was obtained from insurance claims data and Kaplan-Meier estimates were calculated for molecularly defined patients. Results: SETD2 expression was significantly increased in left-sided/rectal compared to right-sided tumors (median TPM [mTPM] 55.8 vs 51.1, q < .001). SETD2 mutations were associated with reduced SETD2 expression in pMMR/MSS CRC (mTPM 37.9 vs 54.3 in WT, q < .001), although not statistically significant in dMMR/MSI-H CRC (mTPM 43.6 vs 51.7 in WT, P = .17). Compared to SETD2-high tumors, SETD2-low was associated with increased rates of TMB-high (10.4% vs 8.2%, P = .009), dMMR/MSI-H (7.3% vs 5.6%, P = .02), and PD-L1 IHC levels (4.4% vs 2.5%, q < .002). Only minor differences in gene mutation and copy number rates were observed between SETD2-high and -low tumors , whereas SETD2-high TME was associated with increased immune cell infiltration, including neutrophils, B cells, NK cells, M2 macrophages, and dendritic cells ( q < .05). SETD2-high was also associated with increased T cell-inflamed and MPAS signatures (152% and 159% median increase, respectively, q < .001), regardless of tumor MMR status. Among dMMR/MSI-H CRC, SETD2-high tumors receiving immune checkpoint inhibitors had longer time-on-treatment (HR: 0.39, 95% CI: 0.2-0.76, P = .005) and a trend towards longer OS (HR: 0.29, 95% CI: 0.07-1.2, P = .069). Conclusions: Our data show distinct immune biomarkers and TME cell infiltration associated with SETD2 gene expression in CRC. These findings support a key role for SETD2 in modulating anti-tumor immunity and TME.
8
Hsu, R., E. N. Maslen y N. Ishizawa. "A synchrotron X-ray study of the electron density in Y2BaCuO5". Acta Crystallographica Section B Structural Science 52, n.º 4 (1 de agosto de 1996): 569–75. http://dx.doi.org/10.1107/s0108768196000250.
Texto completoResumen
The deformation density (Δρ) for Y2BaCuO5, barium diyttrium cuprate, determined by single-crystal X-ray diffraction with synchrotron radiation, is affected to only a limited degree by the bonding interactions involving the O anions. Electron density is strongly depleted along the cation–cation contacts within the mirror plane in the structure and is transferred to regions between mirror planes that do not lie along short cation–cation vectors. The structural geometry for the CuO5 moiety, with the Cu atom in the +2 state, closely resembles that of the Cu2O5 group in YBa2Cu3O7−δ , for which the +3 state involvement for Cu has been suggested. Space group Pnma, orthorhombic, Mr = 458.68, a = 12.1793 (7), b = 5.6591 (5), c = 7.1323 (4) Å, V = 491.6 Å3, Z = 4, Dx = 6.197 Mg m−3, λ = 0.9 Å, μ 0.9 = 28.893 mm−1, F(000) = 812, T = 293 K, R = 0.020, wR = 0.020, S = 3.09 (5) for 2225 unique reflections.
9
Bradford, Porcia T., Susan S. Devesa, William F. Anderson y Jorge R. Toro. "Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases". Blood 113, n.º 21 (21 de mayo de 2009): 5064–73. http://dx.doi.org/10.1182/blood-2008-10-184168.
Texto completoResumen
Abstract There have been no prior large population-based studies focusing on cutaneous lymphomas (CL) in the United States. Using the Surveillance, Epidemiology and End Results (SEER) program data, we analyzed age-adjusted CL incidence rates (IRs) and survival rates by sex and race/ethnicity. There were 3884 CLs diagnosed during 2001-2005. Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (age-adjusted incidence rate [IR] = 7.7/1 000 000 person-years), whereas cutaneous B-cell lymphomas(CBCLs) accounted for 29% (IR = 3.1/1 000 000 person-years). Males had a statistically significant higher IR of CL than females (14.0 vs 8.2/1 000 000 person-years, respectively; male-female IR ratio [M/F IRR] = 1.72; P < .001). CL IRs were highest among blacks and non-Hispanic whites (both 11.5/1 000 000 person-years), followed by Hispanic whites (7.9) and Asian/Pacific Islanders (7.1). The CTCL IR was highest among blacks (10.0/1 000 000 person-years), whereas the CBCL IR was highest among non-Hispanic whites (3.5). Over the past 25 years, the CL IR increased from 5.0/1 000 000 person-years during 1980-1982 to 14.3 during 2001-2003. During 2004-2005, the CL IR was 12.7. This recent apparent change could be incomplete case ascertainment or potential leveling off of IRs. CLs rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.
10
Held, Gerhard, Samira Zeynalova, Niels Murawski, Marita Ziepert, Barbara Kempf, Andreas Viardot, Martin Dreyling et al. "Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement". Journal of Clinical Oncology 31, n.º 32 (10 de noviembre de 2013): 4115–22. http://dx.doi.org/10.1200/jco.2012.48.0467.
Texto completoResumen
Purpose To study clinical presentation, outcome, and the role of radiotherapy in patients with aggressive B-cell lymphoma and skeletal involvement treated with and without rituximab. Patients and Methods Outcome of patients with skeletal involvement was analyzed in a retrospective study of nine consecutive prospective trials of the German High-Grade Non-Hodgkin lymphoma Study Group. Results Of 3,840 patients, 292 (7.6%) had skeletal involvement. In the MabThera International Trial (MInT) for young good-prognosis patients and the Rituximab With CHOP Over 60 Years (RICOVER-60) study for elderly patients, the randomized addition of rituximab improved event-free survival (EFS; hazard ratio for MInT [HRMInT] = 0.4, P > 001; hazard ratio for RICOVER-60 [HRRICOVER-60] = 0.6, P > .001) and overall survival (OS; HRMInT = 0.4, P < .001; HRRICOVER-60 = 0.7, P = .002) in patients without skeletal involvement, but failed to improve the outcome of patients with skeletal involvement (EFS: HRMInT = 1.4, P = .444; HRRICOVER-60 = 0.8, P = .449; OS: HRMInT = 0.6, P = .449; HRRICOVER-60 = 1.0, P = .935). Skeletal involvement was associated with a worse outcome after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (HREFS = 1.5, P = .048; HROS = 1.1; P = .828), but not after CHOP without rituximab (HREFS = 0.8, P = .181; HROS = 0.7, P = .083). In contrast to rituximab, additive radiotherapy to sites of skeletal involvement was associated with a decreased risk (HREFS = 0.3, P = .001; HROS = 0.5; P = .111). Conclusion Rituximab failed to improve the outcome of patients with diffuse large B-cell lymphoma with skeletal involvement, although our data suggest a beneficial effect of radiotherapy to sites of skeletal involvement. Whether radiotherapy to sites of skeletal involvement can be spared in cases with a negative positron emission tomography after immunochemotherapy should be addressed in appropriately designed prospective trials.
11
Witzens-Harig, Mathias, Anthony D. Ho, Evelyn Kuhnt, Marek Trneny, Michael Rieger, Anders Österborg, Ruth Pettengell et al. "Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study". Blood 120, n.º 21 (16 de noviembre de 2012): 1612. http://dx.doi.org/10.1182/blood.v120.21.1612.1612.
Texto completoResumen
Abstract Abstract 1612 Purpose The aim of this subgroup analysis of the MInT study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL). Extended follow-up was needed to establish long-term effects. Patients and Methods Eligible for the randomized open-label MInT study were patients aged 18–60 years with DLBCL who had 0–1 risk factors according to age-adjusted International Prognostic Index (aaIPI), stage II-IV disease, or stage I disease with bulk. Patients were randomly assigned to six cycles of CHOP-like regimens with or without rituximab. Consolidating radiotherapy was given to sites of primary bulky disease. Results Of 824 patients enrolled, 87 had PMBCL and 627 other types of DLBCL. Rituximab increased the rates of complete remission (unconfirmed) in both PMBCL (from 54% to 80%; p =.015) and DLBCL (from 72% to 87%; p<.001). In PMBCL rituximab virtually eliminated progressive disease (PD) (2.5% vs 24%; p =.006), whereas without rituximab PD was more frequent in PMBCL than in DLBCL (24% vs 10%; p =.023). With a median observation time of 62 months for PMBCL and 73 months for DLBCL, the 5-year event-free survival was improved by rituximab for PMBCL (79.1% vs 47.3%; p =.011) and for DLBCL (76.9% vs 59.7%; p <.001). Furthermore, 5-year progression-free survival was improved by rituximab for PMBCL (89.8% vs 60.1%; p=.006) and DLBCL (81.1% vs. 67.8%; p <.001). Overall survival benefit was similar for DLBCL (92.0% vs 80.9%; p <.001) and PMBCL (90.2% vs 78.3%; p =.234). Conclusion Addition of rituximab to 6 cycles of CHOP-like chemotherapy improved long-term outcome for young patients with PMBCL and aaIPI 0–1 and eliminated differences in outcome between PMBCL and DLBCL. Disclosures: No relevant conflicts of interest to declare.
12
Liu, Huimin, Wenjie Xiong, Heng Li, Rui Lv, Wei Liu, Shuhua Yi, Zengjun Li y Lugui Qiu. "Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China". Blood 128, n.º 22 (2 de diciembre de 2016): 5336. http://dx.doi.org/10.1182/blood.v128.22.5336.5336.
Texto completoResumen
Abstract Background: B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several indolent lymphoma subtypes with similar characteristics but also difference and heterogeneity. Several prognostic systems had been established for separate subtypes, such as Rai/Binet stage system for CLL, FLIPI for follicular lymphoma. Here, we want to explore the prognostic role of some common clinical characteristics in each lymphoma subtype, such as serum LDH. Materials and methods: The clinical data of 829 patients with B-CLPD including clinical features, LDH expression level, cytogenetic abnormalities and therapeutic outcome were analyzed retrospectively in department of lymphoma & myeloma, Institute of hematology & Blood disease hospital from April 1990 to August 2013, and the prognosis of B-CLPD patients with different expression levels of LDH was compared, including overall survival (OS) and progression-free survival (PFS) rates. Results: 829 patients were divided into three groups, including 426 (51.4%) patients with chronic lymphocytic lymphoma (CLL), 307 (37.0%) patients with non-CLL B-CLPD and 96 (11.6%) patients with BLPD-U. Elevated serum LDH at diagnosis was detected in 112 (26.3%), 85 (27.7%) and 23 (24.9%) of CLL, non-CLL B-CLPD and BLPD-U group, respectively. Patients with elevated LDH B-CLPD had poorer 5-year overall survival rate (CLL: 63.8% vs 83.0%; non-CLL B-CLPD: 62.2% vs 78.1%; BLPD-U: 47.4% vs 88.6%) and 5-year progression-free survival rate (CLL: 52.0% vs 78.2%; non-CLL B-CLPD: 40.8% vs 75.6%; BLPD-U: 48.9% vs 89.5%) than LDH normal patients. Univariate analysis showed that LDH expression, hemoglobin level, platelet count, B symptoms, P53 deletion were prognostic factors for CLL patient survival, while LDH expression, platelet count, albumin level affected non-CLL B-CLPD patient survival significantly and LDH expression, albumin level, ECOG PS scores for BLPD-U patient survival. Multivariate analysis showed that elevated LDH was an independent significant prognostic factor for overall survival (P<.001) and progression-free survival (P<.001) in all three groups. Conclusion s: Based on these data, we conclude that elevated serum LDH at diagnosis is an unfavorable prognostic factor in patients with B-CLPD. Disclosures No relevant conflicts of interest to declare.
13
Urashima, M., A. Ogata, D. Chauhan, M. Hatziyanni, MB Vidriales, DA Dedera, RL Schlossman y KC Anderson. "Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells". Blood 87, n.º 5 (1 de marzo de 1996): 1928–38. http://dx.doi.org/10.1182/blood.v87.5.1928.1928.
Texto completoResumen
Abstract Interleukin-6 (IL-6), a product of bone marrow stromal cells (BMSCs), is a growth factor for multiple myeloma (MM) cells. Transforming growth factor-beta1 (TGF-beta1) is also produced by BMSCs and can regulate IL- 6 secretion by several tissues, including BMSCs. The present study was designed to characterize in vitro tumor growth regulation by TGF-beta1 in MM. Sorted CD38+CD45RA- MM cells secreted significantly more TGF- beta1 (8.2 +/- 2.0 ng/mL) than peripheral blood mononuclear cells (P < .001), splenic B cells (P < .001), and CD40 ligand (CD40L) pretreated B cells (P < .05). TGF-beta1 secretion by MM-BMMCs (3.8 +/- 0.9 ng/mL) was significantly greater than by N-BMMCs (1.2 +/- 0.1 ng/mL, P < .001). MM-BMSCs also secreted significantly more TGF-beta1 (6.6 +/- 2.5 ng/mL, n = 11) than N-BMSCs (4.4 +/- 0.6 ng/mL, P < .02, n = 10) and N- BMSC lines (3.9 +/- 0.2 ng/mL, P < .02, n = 6). TGF-beta1 secretion was correlated with IL-6 secretion in MM-BMSCs. Anti-TGF-beta1 monoclonal antibody both blocked IL-6 secretion by BMSCs and inhibited the increments in IL-6 secretion by BMSCs induced by MM cell adhesion. Moreover, exogenous TGF-beta1 upregulated IL-6 secretion by MM-BMSCs, normal BMSCs, and CD38+ CD45RA- MM cells, as well as tumor cell proliferation. This is in contrast to the inhibitory effect of TGF- beta1 on proliferation and Ig secretion of normal splenic B cells. Finally, retinoblastoma proteins (pRB) are constitutively phosphorylated in MM cells; TGF-beta1 either did not alter or increased pRB phosphorylation. pRB are dephosphorylated in splenic B cells and phosphorylated in CD40L triggered B cells in contrast to its effects on MM cells, TGF-beta1 decreased phosphorylation of pRB in CD40L treated B cells. These results suggest that TGF-beta1 is produced in MM by both tumor cells and BMSCs, with related tumore cell growth. Moreover, MM cell growth may be enhanced by resistance of tumor cells to the inhibitory effects of TGF-beta1 on normal B-cell proliferation and Ig secretion.
14
Urashima, M., A. Ogata, D. Chauhan, M. Hatziyanni, MB Vidriales, DA Dedera, RL Schlossman y KC Anderson. "Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells". Blood 87, n.º 5 (1 de marzo de 1996): 1928–38. http://dx.doi.org/10.1182/blood.v87.5.1928.bloodjournal8751928.
Texto completoResumen
Interleukin-6 (IL-6), a product of bone marrow stromal cells (BMSCs), is a growth factor for multiple myeloma (MM) cells. Transforming growth factor-beta1 (TGF-beta1) is also produced by BMSCs and can regulate IL- 6 secretion by several tissues, including BMSCs. The present study was designed to characterize in vitro tumor growth regulation by TGF-beta1 in MM. Sorted CD38+CD45RA- MM cells secreted significantly more TGF- beta1 (8.2 +/- 2.0 ng/mL) than peripheral blood mononuclear cells (P < .001), splenic B cells (P < .001), and CD40 ligand (CD40L) pretreated B cells (P < .05). TGF-beta1 secretion by MM-BMMCs (3.8 +/- 0.9 ng/mL) was significantly greater than by N-BMMCs (1.2 +/- 0.1 ng/mL, P < .001). MM-BMSCs also secreted significantly more TGF-beta1 (6.6 +/- 2.5 ng/mL, n = 11) than N-BMSCs (4.4 +/- 0.6 ng/mL, P < .02, n = 10) and N- BMSC lines (3.9 +/- 0.2 ng/mL, P < .02, n = 6). TGF-beta1 secretion was correlated with IL-6 secretion in MM-BMSCs. Anti-TGF-beta1 monoclonal antibody both blocked IL-6 secretion by BMSCs and inhibited the increments in IL-6 secretion by BMSCs induced by MM cell adhesion. Moreover, exogenous TGF-beta1 upregulated IL-6 secretion by MM-BMSCs, normal BMSCs, and CD38+ CD45RA- MM cells, as well as tumor cell proliferation. This is in contrast to the inhibitory effect of TGF- beta1 on proliferation and Ig secretion of normal splenic B cells. Finally, retinoblastoma proteins (pRB) are constitutively phosphorylated in MM cells; TGF-beta1 either did not alter or increased pRB phosphorylation. pRB are dephosphorylated in splenic B cells and phosphorylated in CD40L triggered B cells in contrast to its effects on MM cells, TGF-beta1 decreased phosphorylation of pRB in CD40L treated B cells. These results suggest that TGF-beta1 is produced in MM by both tumor cells and BMSCs, with related tumore cell growth. Moreover, MM cell growth may be enhanced by resistance of tumor cells to the inhibitory effects of TGF-beta1 on normal B-cell proliferation and Ig secretion.
15
Cotecchia, Federica. "Book review: Image analysisImage analysis. SmartP. Glasgow University Press, 2007. 158 pp. ISBN: 978-0-85261-829-5. £15". Géotechnique 60, n.º 7 (julio de 2010): 575. http://dx.doi.org/10.1680/geot.9.b.001.
Texto completo
16
Resnick, Elena S., Erin L. Moshier, James H. Godbold y Charlotte Cunningham-Rundles. "Morbidity and mortality in common variable immune deficiency over 4 decades". Blood 119, n.º 7 (16 de febrero de 2012): 1650–57. http://dx.doi.org/10.1182/blood-2011-09-377945.
Texto completoResumen
Abstract The demographics, immunologic parameters, medical complications, and mortality statistics from 473 subjects with common variable immune deficiency followed over 4 decades in New York were analyzed. Median immunoglobulin levels were IgG, 246 mg/dL; IgA, 8 mg/dL; and IgM, 21 mg/dL; 22.6% had an IgG less than 100 mg/dL. Males were diagnosed earlier (median age, 30 years) than females (median age, 33.5 years; P = .004). Ninety-four percent of patients had a history of infections; 68% also had noninfectious complications: hematologic or organ-specific autoimmunity, 28.6%; chronic lung disease, 28.5%; bronchiectasis, 11.2%; gastrointestinal inflammatory disease, 15.4%; malabsorption, 5.9%; granulomatous disease, 9.7%; liver diseases and hepatitis, 9.1%; lymphoma, 8.2%; or other cancers, 7.0%. Females had higher baseline serum IgM (P = .009) and were more likely to develop lymphoma (P = .04); 19.6% of patients died, a significantly shorter survival than age- and sex-matched population controls (P < .0001). Reduced survival was associated with age at diagnosis, lower baseline IgG, higher IgM, and fewer peripheral B cells. The risk of death was 11 times higher for patients with noninfectious complications (hazard ratio = 10.95; P < .0001). Mortality was associated with lymphoma, any form of hepatitis, functional or structural lung impairment, and gastrointestinal disease with or without malabsorption, but not with bronchiectasis, autoimmunity, other cancers, granulomatous disease, or previous splenectomy.
17
Bernholt, David L., Nicholas N. DePhillipo, W. Jeffrey Grantham, Matthew D. Crawford, Zachary S. Aman, Mitchell Iung Kennedy y Robert F. LaPrade. "Morphologic Variants of Posterolateral Tibial Plateau Impaction Fractures in the Setting of Primary Anterior Cruciate Ligament Tear". American Journal of Sports Medicine 48, n.º 2 (3 de enero de 2020): 318–25. http://dx.doi.org/10.1177/0363546519893709.
Texto completoResumen
Background: Impaction fractures of the posterolateral tibial plateau commonly occur in the setting of anterior cruciate ligament (ACL) tears, with considerable variability found in fracture size and morphologic features. Purpose: The primary objective was to characterize different morphologic variants of posterolateral tibial plateau impaction fractures. The secondary objective was to investigate the association between these impaction fracture variants and concomitant meniscal and ligamentous injuries. Study Design: Cross-sectional study; Level of evidence 3. Methods: Patients treated for primary ACL tears and having magnetic resonance imaging available were included in this study, and magnetic resonance images were reviewed with denotation of displaced posterolateral tibial impaction fractures. A classification system was created based on morphologic variants of impaction fractures; associations were evaluated through use of independent chi-square testing. Results: There were 825 knees meeting the inclusion criteria, with displaced posterolateral tibial plateau impaction fractures present in 407 knees (49.3%). We observed 3 distinct morphologic variants of lateral tibial plateau impaction fractures: (I) posterior cortical buckle not involving the articular surface; (II) posterior impaction fracture involving the articular surface, with subtypes based on (A) tibial plateau depth bone loss <10% and (B) bone loss >10%; and (III) displaced osteochondral fragment, with subtypes for (A) shear or (B) depressed fragment. Type IIIA impaction fractures were associated with an increased incidence of lateral meniscus posterior root tears (33.3% vs 12.4%; P = .009) and an increased incidence of lateral meniscal tears (83.3% vs 56.7%; P = .024) compared with all knees without type IIIA impaction fracture. An increased incidence of medial collateral ligament (MCL) tears was noted in patients with type IIIA impaction fractures compared with those who had no fracture or had another fracture type (61.1% vs 20.1%; P < .001). Type IIIB impaction fractures were associated with an increased incidence of lateral meniscal tears (80.0% vs 56.2%; P = .005). Conclusion: A high prevalence of displaced posterolateral tibial plateau impaction fractures occur in the setting of ACL tears, and they can be classified into distinct morphologic subtypes. Posterolateral tibial plateau impaction fractures with displaced depressed or shear fragments were both associated with an increased incidence of lateral meniscal tears, whereas impaction fractures with a shear fragment were associated with an increased incidence of lateral meniscus posterior root tears and MCL tears.
18
Castagnini, L., C. Manrique, J. Mere y M. García Hjarles. "Determinación de los niveles séricos de b-hCG como predictor de preeclampsia". Revista Peruana de Ginecología y Obstetricia 50, n.º 1 (7 de mayo de 2015): 19–23. http://dx.doi.org/10.31403/rpgo.v50i435.
Texto completoResumen
OBJETIVO: Determinar si la elevación de las gonadotropinas coriónicas beta (ßhCG) en el segundo trimestre del embarazo es un marcador sérico útil para predecir la preeclampsia. DISEÑO: Estudio analítico observacional, tipo casos y control, que empleó casos incidentes. MATERIAL Y MÉTODOS: A las gestantes que tenían entre 14 y 21 semanas de gestación, se les tomó una muestra de suero para la medición de la ßhCG. Se les siguió hasta el final del embarazo. La variable resultado fue la preeclampsia, que dividió a las pacientes en el grupo de los casos (30) y controles (90). RESULTADOS: La media de los valores séricos de la ßhCG fue 92 086,67±76 584,65 mUI/mL en los casos y 69 796,67 ±55 929,25 mUI/mL en el grupo de controles (p = 0,15). El riesgo de tener la b-hCG por encima de 153 000 mUI/mL y de 204 000 mUI/mL en las pacientes con preeclampsia fue 3,72(1,26 -11,05) y 6,77 (1,17- 39,07), respectivamente. Las pacientes con preeclampsia severa tuvieron un riesgo 8,2 (1,9 - 36,8) veces mayor de tener niveles de la hormona mayores de 153 000 mUl/mL que las que no tuvieron enfermedad. CONCLUSIÓN: La ßhCG podría ser utilizada como un marcador sérico para predecir preeclampsia.
19
Lee, S. F. y C. W. Forsberg. "Purification and characterization of an α-L-arabinofuranosidase from Clostridium acetobutylicum ATCC 824". Canadian Journal of Microbiology 33, n.º 11 (1 de noviembre de 1987): 1011–16. http://dx.doi.org/10.1139/m87-178.
Texto completoResumen
An α-L-arabinofuranosidase (EC 3.2.1.55) has been purified from the extracellular culture fluid of Clostridium acetobutylicum ATCC 824 and characterized. The enzyme was a single polypeptide with a molecular weight of 94 000, an isoelectric point of 8.15, and a pH optimum between pH 5.0 and 5.5. The Km and Vmax values for p-nitrophenyl-α-L-arabinofuranoside were 4.0 mM and 36.4 μmol∙min−1·mg protein−1, respectively. The enzyme had practically no activity against other p-nitrophenylglycosides with the exception of p-nitrophenyl-α-D-glucoside which it hydrolysed at 9% of the rate exhibited on p-nitrophenyl-α-L-arabinofuranoside. It degraded arabinan in an exo-manner, but exhibited no activity on carboxymethylcellulose, arabinogalactan, arabinoxylan, or oat spelt xylan. However, when it was incubated with the purified xylanase B, also obtained from C. acetobutylicum, it acted cooperatively to increase the rate of hydrolysis of oat spelt xylan. Arabinose was detected as one of the hydrolysis products.
20
Roca Suarez, Armando Andres y Fabien Zoulim. "Opportunities and challenges for hepatitis B cure". eGastroenterology 1, n.º 2 (octubre de 2023): e100021. http://dx.doi.org/10.1136/egastro-2023-100021.
Texto completoResumen
In spite of the fact that safe and effective vaccines have been available for over 40 years, hepatitis B virus (HBV) remains a major public health problem, as there are 296 million chronically HBV-infected individuals worldwide and 820 000 HBV-related deaths taking place every year. Achieving the goal of HBV cure remains a challenge due to the particularities of the HBV cycle underlying viral persistence. The new understanding of HBV biology and antiviral immune responses has allowed to identify novel drug targets. This has led to a renewed interest in developing new curative strategies and combinations for HBV. In the present review, we aim to summarise the biological and clinical challenges associated with chronic HBV infection. Moreover, we consider the lessons that have been learnt in the past years regarding the preclinical and clinical evaluation of compounds against HBV and how this is driving the field to explore new directions.
21
Broen, Tiana, Yoonseok Choi, Theresa Pauly, Elizabeth Zambrano Garza, Denis Gerstorf y Christiane Hoppmann. "TIME-VARYING ASSOCIATIONS BETWEEN SOCIAL INTERACTION MODALITY AND POSITIVE AFFECT DURING TIMES OF CHALLENGE". Innovation in Aging 6, Supplement_1 (1 de noviembre de 2022): 578. http://dx.doi.org/10.1093/geroni/igac059.2173.
Texto completoResumen
Abstract The COVID-19 pandemic compromised psychological wellbeing, especially given public health guidance that restricted social contact. Engaging in daily social interactions is especially important for maintaining wellbeing, and virtual interactions may be a surrogate for face-to-face interactions when in-person contact is not possible. Embracing the idea that virtual communication may facilitate social connectedness, this project seeks to better understand the potential of virtual social interactions for supporting wellbeing. Using repeated-daily-life-assessments from an adult lifespan sample (N=164, Mage=42.53 years), we examined how number of virtual and face-to-face social interactions were associated with positive affect in individuals’ daily lives. We expected that face-to-face interactions would have a stronger relationship with positive affect than virtual social interactions, but that engaging in virtual interactions would be positively related to affect during these unprecedented times. In line with our hypotheses, number of daily in-person (r(812)=0.14, p<.001) and total number of social interactions (r(812)=0.14, p<.001) were associated with higher positive affect at the bivariate level; number of daily virtual social interactions showed a positive trend with affect (r(812)=0.06, p=.07). Multilevel models including quantity of face-to-face and virtual interactions indicate that only face-to-face interactions were associated with concurrent elevations in positive affect (b=0.58, p=.03) and overall higher positive affect (b=0.72, p<.001). Future analyses will examine whether social interactions involving close ties are more powerful drivers of positive affect than distal ties, whether everyday closeness to others mediates the relationship between social interaction modality and positive affect, and we will unpack age as a moderator in these relationships.
22
Orange, J. S. y M. J. May. "Cell penetrating peptide inhibitors of Nuclear Factor-kappa B". Cellular and Molecular Life Sciences 65, n.º 22 (1 de agosto de 2008): 3564–91. http://dx.doi.org/10.1007/s00018-008-8222-z.
Texto completo
23
Bleker de Oliveira, Mariana, Veruska Lia Fook Alves, Angela Isabel Eugenio, Rodrigo Carlini Fernando, Mihoko Yamamoto y Gisele W. B. Colleoni. "In Vitro JAK1/2 Inhibition, in Association with Bortezomib and Lenalidomide, Is Comparable with Bortezomib, Lenalidomide and Dexametasone: An Alternative for Multiple Myeloma Patients with JAK2 overexpression?" Blood 128, n.º 22 (2 de diciembre de 2016): 5663. http://dx.doi.org/10.1182/blood.v128.22.5663.5663.
Texto completoResumen
Abstract Background: Despite the absence of JAK1 and JAK2 mutations in multiple myeloma (MM), high levels of IL-6 constitutively activate the JAK/STAT pathway promoting survival and proliferation of tumor cells. Therefore, pharmacological inhibition of JAK proteins can be a potentially therapeutic strategy for myeloma treatment. Aims: 1) to identify expression of JAK1 and JAK2 in MM cell lines and in recently diagnosed MM patients; 2) to perform functional in vitro studies in MM cell lines treated with JAK/STAT pathway inhibitor (ruxolitinib), associated with drugs currently used in MM first line treatment (bortezomib, lenalidomide and dexamethasone), with and without co-culture with normal stromal cells; 3) to evaluate global gene expression of JAK/STAT pathway in cell lines treated with ruxolitinib to elucidate its mechanism of action in MM. Methods: JAK1 and JAK2 expression were analyzed in four cell lines (RPMI-8226, U266, SKO-007 and SKM-M2) and in bone marrow samples from 30 MM patients and 3 healthy controls by real time PCR. After IC50 calculation, drugs concentrations were: bortezomib (B) 10 nM for both RPMI-8226 and U266 cell lines; ruxolitinib (R) 30 µM for RPMI-8226 and 40 µM for U266 cell lines; lenalidomide (L) 10 µM for both cell lines; and dexamethasone (D) 1 µM for both cell lines. Apoptosis and cell cycle were evaluated by flow cytometry. PCR array for 92 JAK/STAT pathway related genes (Taqman® Array Human JAK/STAT Pathway, Applied Biosystems, Foster City, CA, USA) was performed in RPMI-8226 and U266 wild type and B+R treated cell lines, in duplicates. Results: Among the four cell lines, U266 presented the highest expression of JAK1 and JAK2 genes. JAK1 was overexpressed in 27% and JAK2 in 57% of 30 MM patients (considering at least 2-fold increase). After B+R treatment, RPMI-8226 showed increased number of cells in SubG0 phase (p<0.001) with reduction of cells in S (p<0.01) and G2/M (p<0.001) phases. In U266 cell line, there is a slight increase of cells in SubG0 phase (p<0.05). Also, after B+R treatment, both RPMI-8226 and U266 presented 50% of cells in late apoptosis, which was accompanied by reduction of expression levels of BCL-2 and BCL-XL anti-apoptotic genes. The expression profile of JAK/STAT pathway after B+R treatment showed that many JAK/STAT, Ras/Raf/MAPK and PI3K/Akt/mTOR pathways genes lost their expression, mainly in RPMI-8226, with insignificant changes in U266 expression pattern. Co-culture of RPMI-8226 with normal stromal cell line HS5 protected tumor cells from apoptosis, as the number of cells in late apoptosis decreased from 50% to 32% (p<0.001). The addition of immunomodulatory drug lenalidomide to the schedule (B+R+L) increased tumor cell death from 32% to 73% in co-culture (p<0.001). Despite the impressive results, B+R+L schedule was equivalent to currently used treatment for standard risk MM patients B+L+D (67% of cell death, p>0.05), in co-culture. Conclusion: B+R combination induced cell cycle arrest and apoptosis in U266 and RPMI-8226. The new drug combination B+R+L has in vitro results comparable with B+L+D and presents an alternative for MM treatment of almost 60% of cases bearing JAK2 overexpression. Our results support future studies using JAK inhibitors as an alternative for MM treatment in a Precision Medicine approach. Financial support: FAPESP 2010/17668-6 and CNPq. Disclosures No relevant conflicts of interest to declare.
24
PETERSON, C., I. ENANDER y P. VENGE. "824 Radioimmunoassay of human eosinophil protein X (EPX/EDN). Establishment of normal levels to serum and plasma and turnover in vivo". Journal of Allergy and Clinical Immunology 87, n.º 1 (enero de 1991): 345. http://dx.doi.org/10.1016/0091-6749(91)92106-b.
Texto completo
25
Wongchaowart, Nicholas, Ena Segota, Tao Jin, Brad Pohlman y Eric D. Hsi. "Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor." Blood 106, n.º 11 (16 de noviembre de 2005): 4706. http://dx.doi.org/10.1182/blood.v106.11.4706.4706.
Texto completoResumen
Abstract Introduction: Diffuse large B-cell lymphoma (DLBL) is a biologically and clinically heterogeneous lymphoma. Gene expression profiling studies using cDNA microarray have led to the development of a new paradigm for the subclassification of DLBL into germinal center B-cell (GCB) and activated B-cell types with a favorable and an unfavorable prognosis, respectively. The expression pattern of CD10, BCL6 and MUM1 by immunohistochemistry (IHC) has been proposed as a surrogate to distinguish GCB from non-GCB types. This immunohistochemical model must be validated in other data sets. Methods: We identified 57 cases of primary nodal DLBL for which the initial diagnostic biopsy, International Prognostic Index (IPI), and clinical follow-up were available. These patients (pts) received CHOP (n=51) or CHOP-like (n=6) chemotherapy, rituximab (n=12), radiation therapy (n=20), and high dose therapy with stem cell transplantation (SCT)(n=6) as planned primary therapy with curative intent. A tissue microarray (TMA) was constructed and cases were assessed for expression of CD10, BCL6, and MUM1. GCB and non-GCB immunophenotypes (IP) were defined as previously described (Hans et al. Blood 2004, 103:272–85). Clinical endpoints were disease progression and death. Analyses were performed using Cox proportional hazards testing. Results: The pts consisted of 32 men and 25 women with median age of 60 (range 29–82) years. 26 pts progressed and 25 pts died. Median follow-up of surviving pts was 69.9 (range 8.3–148.1) months. 64%, 82%, and 58% of cases expressed CD10, BCL6, and MUM 1, respectively, and 69% had a GCB IP using the Hans criteria. Univariate analysis showed that high IPI and MUM1 expression predicted a higher risk of progression (P<.001 and P=.027) while IPI, MUM1, and GCB IP predicted a higher risk of death (P<.001, P=.031, and P=.023). BCL6 expression was associated with a trend toward a lower risk of progression (P=.10) but not death (P=.38). By multivariate analysis, high IPI and MUM1 expression remained independent predictors of both progression (HR 7.07, 95% CI 2.68–18.63, P<.001 and HR=3.88, 95% CI 1.51–9.95, P=.005, respectively) and death (HR 6.48, 95% CI 2.57–16.34, P<.001 and HR 3.21, 95% CI 1.25–825, P.015, respectively) while BCL6 expression predicted a lower risk of progression only (HR 0.29, 95% CI 0.11–0.74, P=0.01). Two re-analyses excluding pts that received rituximab or SCT as a planned part of primary therapy gave similar results. Conclusions: We were unable to confirm the significance of GCB vs non-GCB types using CD10, BCL6, and MUM1 immuhistochemical expression patterns as independent predictors of either progression or death in this cohort of nodal DLBL. However, MUM1 expression (in addition to high IPI) was an independent predictor of a higher risk of both disease progression and death. BCL6 was an independent predictor of a lower risk of disease progression. BCL6 and MUM1 assessment using IHC in nodal DLBL provides useful prognostic information and simplifies pathological risk stratification of nodal DLBL from 3 to 2 markers. These data require confirmation in a larger, independent cohort of nodal DLBL pts treated with a rituximab-containing chemotherapy regimen.
26
Livadas, Sarantis, I. Androulakis, A. Kollias, R. D. Paparodis, N. Angelopoulos, A. Boniakos, D. Askitis, P. Anagnostis y L. Duntas. "LBSAT247 Factors Guiding Successful Treatment Discontinuation In Levothyroxine Replacement Therapy Overuse: Short And Long-term Observation Data Of 802 Subjects." Journal of the Endocrine Society 6, Supplement_1 (1 de noviembre de 2022): A745. http://dx.doi.org/10.1210/jendso/bvac150.1537.
Texto completoResumen
Abstract Background Levothyroxine (LT4-Rx) is one of the most commonly prescribed drugs worldwide and the vast majority of patients receive long-term treatment. However, in a recent study of LT4-Rx withdrawal in 291 subjects, it was found that 60% of those remained biochemically euthyroid two months after LT4-Rx discontinuation1. Aim of the study A prospective clinical cohort follow-up study was carried out to address this issue. We registered all patients presented in our clinical practice who were not on LT4-Rx for a solid diagnosis of hypothyroidism and abruptly discontinued treatment. All subjects underwent weight, height, TSH, TPO, Tg-Abs and free T4 measurement and thyroid ultrasound on enrolment, 2-4 months later, and at the end of follow up. A TSH value of ≥4.5IU/mL was considered as underlying hypothyroidism. Results We enrolled 802 consecutive subjects (83% females) aged 48±16 (range 18-84 years) with 8.8±7.3 years on LT4-Rx. The treatment indications and corresponding percentage for LT4-Rx were classified as a nodule(s) (35%), indefinite (25%), post-partum (7%) and Hashimoto's (33%); 48% of subjects were part of Group A and long-term follow-up up to 5 years was achieved in the remaining. Among the entire cohort, n=182 subjects became hypothyroid, while the remaining n=620 remained euthyroid off LT4-Rx (23 vs. 77%, p<0. 001). On subgroup analysis, 40% of subjects comprising Group A became hypothyroid, whereas the corresponding value for Group B was 7%. In Group A, the reason for LT4-Rx, LT4 dose, LT4 dose/BMI, TSH levels and the presence of increased thyroid autoantibodies titers (ATA) were significantly different in those who became hypothyroid, whereas only the reason for LT4-Rx differed in Group B. Subjects with a diagnosis of nodules, negative ATA, lower TSH values and lower LT4 dose during treatment had significantly lower probability to become hypothyroid. Furthermore, in Group A, 14.8% became hypothyroid with baseline TSH>3IU/mL vs. 5.2% with baseline TSH<3IU/mL (p<0. 001); the corresponding values for Group B were 22.2% vs. 8.8%, (p<0. 001), respectively. Conclusions These findings suggest considerable overuse of thyroxine therapy. In cases of uncertainty, the existence of nodules, a low-normal TSH value, a relatively small T4 dose, and the absence of ATA are strong predictors of euthyroidism, and accordingly a treatment discontinuation trial is recommended. Furthermore, if hypothyroidism does not ensue 2-4 months post-treatment discontinuation, the likelihood to develop hypothyroidism in the long term is minimal.1. Livadas S, et al. Thyroid 2018. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.
27
Fisher, S. N. y N. Suramlishvili. "Coherently Precessing Spin and Orbital States in Superfluid 3He–B". Journal of Low Temperature Physics 141, n.º 3-4 (noviembre de 2005): 111–41. http://dx.doi.org/10.1007/s10909-005-8224-2.
Texto completo
28
Suwardike, Putu, I. Nyoman Rai, Rindang Dwiyani y Eniek Kriswiyanti. "DNA POLYMORPHISM AND GENETIC DIVERSITY OF MANGO (Mangifera sp.) GERMPLASM IN TROPICAL ISLAND". International Journal of Biosciences and Biotechnology 7, n.º 1 (14 de marzo de 2020): 45. http://dx.doi.org/10.24843/ijbb.2019.v07.i01.p05.
Texto completoResumen
Creation of new superior varieties of mango through the empowerment of local genetic resources requires information about the potential properties of mango germplasm, including DNA polymorphism and its genetic diversity. This research aimed to obtain basic data on DNA polymorphism, genetic relationship, genetic similarity level, and molecular accession of Bali’s unique local mango. Sampling was conducted in four regencies in the Province of Bali. DNA preparation, PCR, and microsatellite analysis were carried out at the Laboratory of Genetics and Plant Breeding, Faculty of Agriculture, Gadjah Mada University. It found 44accessions of mangoes in Bali. The test results with 10 pairs of SSR markers showed that all primers produced polymorphic loci. There were 825 amplified DNA bands. Primer of AY31 produced the highest number of loci, which were 14 loci, while AY21 produced the fewest loci, i.e., 3 loci. Forty-four mango accessions showed a genetic similarity coefficient of 0.27 to 0.97. At a coefficient of 0.27, accessions were divided into 2 major groups: group A and group B. Group A consisted of two accessions, namely, KRA-005 and BDG-006 (Mangifera foetida Lour.), which had a similar coefficient of 0.657. Group B was divided into twosmaller groups, namely, groups B1 and B2, at a similarity coefficient of 0.342. Group B1 consisted of 39 accessions, while group B2 consisted of 3 accessions. Accessions Madu Anggur, Gading, Sambuk Mengwi, Kakul and Pakel Sulangai were identified as having unique alleles.
29
Claviez, Alexander, Markus Tiemann, Heike Lueders, Reza Parwaresch, Guenther Schellong y Wolfgang Doerffel. "The Impact of Latent Epstein-Barr Virus Infection on Outcome in Children and Adolescents with Hodgkin’s Lymphoma." Blood 104, n.º 11 (16 de noviembre de 2004): 3121. http://dx.doi.org/10.1182/blood.v104.11.3121.3121.
Texto completoResumen
Abstract The prognostic significance of latent Epstein-Barr virus (EBV) infection in Hodgkin’s lymphoma (HL) is debated controversially. Especially in the pediatric age group, no conclusive data are available due to small series. 842 children and adolescents (55% male) with a median age of 13.7 years (range, 2–20) from consecutive pediatric DAL/GPOH multicenter treatment studies HD-90 and HD-95 were studied for the presence of latent EBV infection in Hodgkin and Reed-Sternberg cells by immunostaining against latent membrane protein 1 (LMP-1). Histology subtypes were as follows: nodular sclerosis (NSHL) 549, mixed cellularity (MCHL) 190, lymphocyte predominance (NLPHL) 90, lymphocyte depletion (LDHL) 6, lymphocyte-rich classical HL (LRCHL) 5, not specified 2. 88 patients had stage I, 470 had stage II, 172 had stage III and 112 had stage IV. B symptoms were present in 274 patients (33%). LMP status was compared with clinical parameters and established risk factors. A total of 263 patients (32%) were LMP positive. EBV infection correlated with gender (male 39% vs. female 23%; p<.001), histological subtype (MCHL 69% vs. NSHL 22% vs. NLPHL 6%; p<.001) and age (<10 years 67% vs ≥10 years 28%, p<.001. With a median follow-up of 4.9 years (0.3–12) 820 patients (97%) are alive. Probability of overall survival at 10 years (±SD) for EBV negative and positive patients was 98±1% and 95±1%, respectively (p=.017 by log-rank test). Probability of failure-free survival (FFS) in LMP positive and negative patients was 89±2% and 84±4%, respectively (p=.86). With respect to LMP status, a negative effect of latent EBV infection on overall survival became evident only for patients treated for advanced stages (p=.003), those with nodular sclerosis subtype Bennett II (p=.02) and B symptoms (p=.05). In a multivariate regression analysis, allocation to treatment group (RR=3.7) and LMP positivity (RR=3.01) were independent factors for overall survival and presence of B symptoms (RR=2.4) for FFS. Under current highly effective polychemotherapy with or without involved field radiotherapy in pediatric HL, latent EBV infection has no influence on FFS in univariate and multivariate analysis. LMP positivity, however, seems to be associated with an inferior overall survival in some subgroups.
30
Campusano, Luis E. "About the QSOs contained in the Cerro el Roble Survey and the density of UVX-QSOs in the SGP field". Symposium - International Astronomical Union 119 (1986): 49–50. http://dx.doi.org/10.1017/s0074180900152222.
Texto completoResumen
A region containing the SGP, centered at α 00h 53m (1950) δ −28°03', is becoming a selected region for QSO research. Three lists of QSO candidates have been published for this field. One consists of candidates discovered visually on an objective prism plate, selected in a 25-deg2 area and with B(lim) ⋍ 20 mag (Clowes and Savage, 1983; the CS sample). The other list came from visual inspection of U and B plates (UVX stars), covering a region of 44-deg2 and with approximately the same limiting magnitude of the CS sample (Campusano and Torres, 1983; the CT sample). The third survey of QSO-candidates involved a machine selection of UVX stars (Shanks et al., 1983), whose published components correspond to two small areas of 1.6 and 8.2 deg2 with B(lim) = 19 mag (Boyle et al., 1985).
31
Papathanassoglou, Elizabeth D. E., Meropi D. A. Mpouzika, Margarita Giannakopoulou, Evangelos Bozas, Nicos Middleton, Sofia Boti y Andreas Karabinis. "Pilot Investigation of the Association Between Serum Stress Neuropeptide Levels and Lymphocyte Expression of Fas and Fas Ligand in Critical Illness". Biological Research For Nursing 17, n.º 3 (18 de septiembre de 2014): 285–94. http://dx.doi.org/10.1177/1099800414542871.
Texto completoResumen
Introduction: In critical illness, apoptotic loss of immunocytes is associated with immunosuppression. Aim: To explore expression of Fas/Fas ligand (FasL) on B and T cells from critically ill patients without sepsis compared to matched controls and associations with disease severity and neuropeptide Y (NPY), cortisol, adrenocorticotropic hormone (ACTH), and prolactin (PRL) levels. Methods: Repeated-measures correlational design with 36 critically ill patients (14-day follow-up) and 36 controls. Disease severity was assessed using the Multiple Organ Dysfunction Score (MODS) and Multi Organ Failure scale. Fas/FasL values were standardized for viable cell counts. An enzyme-linked immunosorbent assay (NPY) and electrochemiluminescence immunoassay (cortisol, ACTH, and PRL) were employed. Results: Fas and FasL expression on T-helper ( p < .0001–.03) and T-cytotoxic cells ( p < .0001–.002) and Fas expression on B cells ( p < .0001–.03) were higher in patients. MODS severity was associated with FasL expression on cytotoxic T cells ( r = .752–.902, p = .023–.037). There was an inverse association between Day 1 NPY levels and Fas expression on T-helper cells ( r = −.447, p = .019). On the day of maximum severity, we report for the first time an inverse association between NPY levels and FasL expression on helper ( r = −.733, p = .016) and cytotoxic ( r = −.862, p = .003) T cells. Cortisol levels were positively associated with counts of FasL-positive helper ( r = .828) and cytotoxic ( r = .544, p < .05) T cells. Conclusion: Results suggest a potential role for stress neuropeptides in lymphocyte survival and activation in critical illness.
32
Zheng, Tao, Tian-Biao Zhang, Kun-Long Lv, Yong-Hao Nan, Yong-Fei Liu, Ya-Wei Hao, Jie Zhang y Rui Wang. "A Comparative Study on the Success Rates of Two Approaches for Seminal Vesiculoscopy". American Journal of Men's Health 16, n.º 4 (julio de 2022): 155798832211156. http://dx.doi.org/10.1177/15579883221115615.
Texto completoResumen
This study aimed to compare the success rates of two approaches for seminal vesiculoscopy: through the interior of the prostatic utricle and through the neck of the prostatic utricle. The patients were divided into two groups based on the seminal vesiculoscopy used. Group A was an interior of the prostatic utricle group (152 cases), and group B was a neck of the prostatic utricle group (146 cases). The general clinical data, intraoperative conditions and surgical results of the two groups were compared. Compared with group A, group B had a higher surgical success rate (94.5% vs. 62.5%, p < .001), a shorter operation time (33 min vs. 45 min, p < .001), less blood loss (0.5 ml vs. 2 ml, p < .001), a higher pain relief rate (86.6% vs. 52.3%, p < .001), a higher remission rate of haemospermia (82.2% vs. 58.5%, p = .011), a lower recurrence rate of pain (10.4% vs. 35.4%, p < .001), a lower recurrence rate of haemospermia (15.6% vs. 37.7%, p = .014), a higher symptom remission rate of the lower urinary tract (90.9% vs. 50.0%, p = .030), a higher remission rate of scrotal moisture (84.6% vs. 45.5%, p = .042) and a higher remission rate of frequent spermatorrhea (80.0% vs. 55.6%, p = .033). Seminal vesiculoscopy undertaken through the neck of the prostatic utricle has the characteristics of high success rate, short operation time and good surgical effect and is worthy of promotion and application.
33
Lichtman, Stuart M., Donna Hollis, Antonius A. Miller, Gary L. Rosner, Chris A. Rhoades, Eric P. Lester, Frederick Millard et al. "Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)". Journal of Clinical Oncology 24, n.º 12 (20 de abril de 2006): 1846–51. http://dx.doi.org/10.1200/jco.2005.03.9289.
Texto completoResumen
Purpose To prospectively evaluate the pharmacokinetics and toxicity profile of paclitaxel in relation to patient age in adults ≥ 55 years old. Patients and Methods Paclitaxel was administered at 175 mg/m2 for 3 hours to 153 patients, 46 of whom were ≥ 75 years of age. Pharmacokinetic and toxicity assessments were performed. Data were analyzed by cohort (cohort 1, age 55 to 64 years; cohort 2, age 65 to 74 years; cohort 3, age ≥ 75 years). Results Paclitaxel concentration versus time (AUC) and total-body clearance (CLtb) data were available for 122 patients (cohort 1, 46 patients; cohort 2, 44 patients; cohort 3, 32 patients). Mean paclitaxel AUC increased across cohorts (P = .01). Mean (SE) AUCs were 22.4 (2.5) μmol/L × hour, 26.2 (2.8) μmol/L × hour, and 31.7 (5.6) μmol/L × hour for cohorts 1, 2, and 3, respectively. There was a corresponding significant (P = .007) age-related decrease in mean (SE) paclitaxel CLtb (cohort 1, 11.0 [0.7] L/h/m2; cohort 2, 9.3 [0.6] L/h/m2; cohort 3, 8.2 [0.6] L/h/m2). Patients in cohort 3 experienced significantly lower absolute neutrophil count nadirs than did younger groups (P = .02). There was also a significant increase in percentage of patients with ≥ grade 3 neutropenia across age cohorts (cohort 1, 22%; cohort 2, 35%; cohort 3, 49%; P = .006). However, the increased exposure of patients to paclitaxel and increased neutropenia were not reflected in adverse clinical sequelae such as hospitalization for toxicity (P = .82), receiving intravenous antibiotics (P = .21), or experiencing a temperature more than 38°C (P = .45). Conclusion Although paclitaxel CLtb decreases with increasing patient age, there is great interpatient variability. Cooperative group studies to evaluate the effect of aging on pharmacokinetics are feasible.
34
Portuguese, Andrew J., Aya Albittar, Emily C. Liang, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Lorenzo Iovino et al. "Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting". Blood 142, Supplement 1 (28 de noviembre de 2023): 2131. http://dx.doi.org/10.1182/blood-2023-172978.
Texto completoResumen
CD19 CAR-T therapy has revolutionized the management of high-risk and relapsed/refractory (R/R) large B-cell lymphoma (LBCL) but remains limited by significant toxicities leading to morbidity/mortality and high resource utilization. Single-arm studies have suggested differences in efficacy and toxicity across FDA-approved CD19 CAR-T products. A matching-adjusted indirect treatment comparison showed comparable efficacy and more favorable safety with lisocabtagene maraleucel (liso-cel) compared to axicabtagene ciloleucel (axi-cel), but was limited to clinical trial patients (pts) and suffered from an absence of patient-level data (Maloney, J Hematol Oncol, 2021). In the absence of randomized clinical trial data, adjusted comparative analyses using pt-level data are critically needed to guide product choice. Therefore, we retrospectively evaluated the impact of CAR-T product type on the outcomes of 129 LBCL pts receiving liso-cel or axi-cel per standard of care. All LBCL pts treated at our center with liso-cel or axi-cel outside of a clinical trial between 1/2018 and 5/2023 were included. Best response was determined within 3 months of CAR-T infusion by PET-CT imaging per Lugano 2014 criteria. Cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS) were graded using ASTCT criteria. Of 129 total pts, 37% (n=48) and 63% (n=81) received liso-cel and axi-cel, respectively. Seven pts received out-of-specification liso-cel on an expanded access protocol. Pts who received liso-cel were older (median 67 vs 62 years, p=.003). Other baseline characteristics, including male sex (liso-cel vs axi-cel: 63% vs 69%, p=.4), HCT-CI score (1.0 vs 1.0, p=.6), pre-lymphodepletion (LD) LDH (178 vs 214 U/L, p=.14) and ALC (0.65 vs 0.60 x 10³/µL, p=.3), largest lesion diameter (3.1 vs 3.0 cm, p=.4), and extranodal disease (56% vs 56%, p>.9) were similar. The vein-to-vein time (time from leukapheresis to CAR-T infusion) was longer for liso-cel: median, 35 vs 27 days (p<.001). After liso-cel, the total inpt duration was shorter (median, 5 vs 14 days, p<.001) and fewer pts had ≥2 admissions (8.3% vs 22%, p=0.043). In pts with measurable disease prior to LD (n=113), we observed comparable efficacy with liso-cel vs axi-cel: ORR, 82% vs 77% (p=.5); CR, 56% vs 51% (p=.8). After a median follow-up of 17.7 months, we observed comparable 1-year outcomes with liso-cel vs axi-cel: duration of response (DOR), 56% vs 61% (p=.7); progression-free survival (PFS), 47% vs 47% (p=.99; Figure); and overall survival (OS), 69% vs 60% (p=.39). In pts evaluable for toxicity assessment (n=129), liso-cel was associated with lower rates of CRS and ICANS compared to axi-cel: any grade CRS, 62% vs 88% (p=.001); ICANS any grade, 32% vs 56% (p=.010); days with fever, median 2 vs 5 days (p<.001). Grade 3-4 CRS, 2.1% vs 9.9% (p=.2) or grade 3-4 ICANS, 23% vs 19% (p=0.5) were similar. We measured lower peak serum inflammatory markers after liso-cel: CRP, 58 vs 114 mg/L (p<.001); ferritin, 622 vs 1,315 ng/mL (p=0.007); IL-6, 55 vs 204 pg/mL (p=.010); and D-dimer, 1.4 vs 2.4 mg/L (p=.017). The incidence of infectious complications after liso-cel vs axi-cel was as follows: bacteremia: 6% vs 9% (p=.7); CMV viremia: 13% vs 6.2% (p=.3). Post-infusion median nadir cytopenias were less severe after liso-cel: ANC, 0.32 vs 0.04 x 10³/µL (p<.001); Plt, 69 vs 35 x 10³/µL (p=.003); and Hgb, 8.9 vs 8.2 g/dL (p<.001). Fewer pts developed severe neutropenia after liso-cel: 72% vs 93% (p=0.002). In multivariable analysis including pre-LD LDH and ALC, largest lesion diameter, age and HCT-CI score, we could not confirm an independent impact of the product type on CR, PFS, or OS ( Table). However, axi-cel remained independently associated with a higher odds of any grade CRS (adjusted OR [aOR] 4.56, 95% CI 1.65-13.5, p=.004) and any grade ICANS (aOR 3.44, 95% CI 1.42-8.85, p=.008). Our analysis of CD19 CAR-T therapy for R/R LBCL in the non-trial setting showed similar rates of durable responses following liso-cel and axi-cel. Pts who received liso-cel were older, with otherwise comparable baseline characteristics. Although liso-cel was associated with less toxicity, its vein-to-vein time was longer. In multivariable analyses, pre-LD LDH and largest lesion diameter were the only factors independently associated with response outcomes. We conclude that liso-cel is a robust alternative to other CD19 CAR-T products in older and frailer LBCL pts.
35
Vetter, Marcus, Karin M. Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker et al. "SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients". Endocrine Oncology 2, n.º 1 (1 de marzo de 2022): 9–18. http://dx.doi.org/10.1530/eo-21-0009.
Texto completoResumen
Objective CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC504.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investigated the efficacy and safety of CR1447 for patients with metastatic estrogen receptor-positive (A) and AR-positive triple-negative breast cancers (B). Design and methods (A) included patients with at most one prior endocrine therapy line without progression ≥6 months, whereas (B) included patients with ≤2 prior chemotherapy lines, all displaying advanced signs of disease. The primary endpoint was disease control at week 24 (DC24). The null hypothesis was DC24 ≤30% (A) and ≤15% (B). Thirty-seven patients were recruited (29 in (A) and 8 in (B)); accrual was stopped following an interim analysis demonstrating futility in (A) and slow accrual in (B). Results DC24 was attained in 5/21 (95% CI: 8.2–47.2) patients in (A) and none in (B). The median progression-free survival was 5.1 months (95% CI: 2.5–5.6) in (A) and 2.5 months (95% CI: 0.7–2.6) in (B). The median overall survival was 24.6 months (95% CI: 22.9–not applicable) in (A) and 10.8 months (95% CI: 3.3–10.9) in (B). CR1447 had a favorable safety profile without treatment-related grade 3–5 toxicities in (A). Especially no side effects linked to androgenic effects were observed. Conclusions Despite this trial being negative, the 24% DC24 rate in a second-line setting, and the prolonged partial response experienced by a patient, indicate activity. Further evaluation of CR1447 in endocrine-sensitive patients or combination trials appears warranted.
36
Döscher, Anja. "Behrendt, Renata; Kreitz, David: Autobiografisches Schreiben in Bildungs-kontexten. Konzepte und Methoden. Bielefeld: wbv Publikation, 2021 (UTB, Theorie und Praxis in der Schreibwissenschaft, 10). – ISBN 978-3-8252-5545-9. 239 Seiten, € 25,00." Informationen Deutsch als Fremdsprache 50, n.º 2-3 (15 de marzo de 2023): 151–54. http://dx.doi.org/10.1515/infodaf-2023-0019.
Texto completo
37
Aujero, Madonna, John Michael Tagsa y Gleno Lon Llamera. "Association of Clinicodemographic Factors and Tissue Biopsy Results Among Patients with Thyroid Nodules at the Southern Philippines Medical Center". Philippine Journal of Otolaryngology Head and Neck Surgery 38, n.º 2 (20 de noviembre de 2023): 26. http://dx.doi.org/10.32412/pjohns.v38i2.2211.
Texto completoResumen
Objective: To compare selected clinicodemographic factors of patients with thyroid nodules who underwent thyroid surgeries with their tissue biopsy results and determine any association between clinicodemographic factors and tissue biopsy results.
Methods:Design: Retrospective review of recordsSetting: Tertiary Government Training HospitalParticipants: 251 patients with thyroid nodules
Results: Of 251 patients with thyroid nodules, the majority (218; 86.9%) were females while 33 (13.1%) were males. The average age in years was 41.5±13.3 The same population also had malignant outcomes at 79.3%. Most of the patients did not have family history of thyroid malignancy (54%) and had no palpable cervical lymph nodes at presentation (75.9%). Furthermore, there was no distant metastasis at presentation for both lungs (97.7%) and bones (98.9%). There were no significant differences in tissue biopsy results when correlated with age (df=249; t=-.144; p = .886), duration of goiter (df=249; t=-.829; p = .408), and distant metastasis at presentation for lungs (Z=-5.977; p = .052) and bones (Z=-.457; p = .648). Significant differences were only evident for clinicodemographic factors such as sex (Z=-2.570; p = .010), family history (Z=-2.239; p = .020), palpable cervical lymph nodes at presentation (Z=-5.977; p = .000), and the following comorbidities: pulmonary tuberculosis (Z=-2.388; p = .017) and bronchial asthma (Z=-2.148; p = .032) and smoking history (Z=-3.455; p=.001). Furthermore, having no palpable cervical lymph nodes at presentation were associated with malignant tissue biopsy results (B=3.616; p=.001). Patients without palpable cervical lymph nodes at presentation were 37.204 times [OR=37.204] more likely to have benign biopsy results [95% CI: 4.705 – 294.168].
Conclusion: There are greater odds of having benign biopsy results for patients without palpable cervical lymph nodes at presentation.
38
Jabłonowski, Zbigniew, Jan Kuydowicz, Marek Sosnowski, Waldemar Różański, Sławomir Jabłośki y Elżbieta Jabłonowska. "Total serum testosterone estimation and ultrasonographic volumetric evaluation of testes in patients with alcoholic liver cirrhosis". Open Medicine 4, n.º 3 (1 de septiembre de 2009): 299–303. http://dx.doi.org/10.2478/s11536-009-0050-5.
Texto completoResumen
AbstractIn the course of cirrhosis, a variety of disturbances of endocrine glands occur. Degenerative changes in the testes with atrophia and fibrosis of the glandular tissue are often found in men. Twenty-one males with compensated alcoholic liver cirrhosis were studied. The age ranged from 29 to 61 years (mean 47,1). Efficiency of the liver was evaluated according to Child classification. HBC (this needs to be spelled out in parenthesis) or HBV (Hepatitis B Virus) infections were excluded. Levels of serum testosterone were determined and the volume size of the testes was measured using 7,5 MHz sector probe, B&K Medical ultrasonograph, 3535 model. Volume size of the testes was measured in 22 healthy control volunteers, as well; age ranged from 25 to 66 years (mean-46,6). All patients were interviewed about sexual function, particularly possible erectile dysfunction using IIEF-5 questionnaire. The mean testosterone level was 8,89 umol/l (ranged: 7,4–10,9 umol/l) in the study patients [the normal range interval: 8,2–34,6 umol/l]. The level was below the normal range in 4 patients, and low but within the normal range in the remaining patients. Statistically significant lower values of both testes volumes were estimated in patients with compensated alcoholic liver cirrhosis in comparison to healthy controls (p<0,001), however only 5 (23,81 %) study group subjects admitted impaired libido and erectile dysfunction. Decreased levels of testosterone in the peripheral blood and diminished volume size of testes are found in patients suffering from alcoholic liver cirrhosis. Erectile dysfunction in patients with liver cirrhosis needs further evaluation.
39
Wiefferink, Alice E. C. M., Patrick W. Weerwind, Waander van Heerde, Steven Teerenstra, Luc Noyez, Ben E. de Pauw y René M. H. J. Brouwer. "Autotransfusion Management During and After Cardiopulmonary Bypass Alters Fibrin Degradation and Transfusion Requirements". Journal of ExtraCorporeal Technology 39, n.º 2 (junio de 2007): 66–70. http://dx.doi.org/10.1051/ject/200739066.
Texto completoResumen
The coagulation-fibrinolytic profile during cardiopulmonary bypass (CPB) has been widely documented. However, less information is available on the possible persistence of these alterations when autotransfusion is used in management of perioperative blood loss. This study was designed to explore the influence of autotransfusion management on intravascular fibrin degradation and postoperative transfusions. Thirty patients, undergoing elective primary isolated coronary bypass grafting, were randomly allocated either to a control group (group A; n = 15) or an intervention group (group B; n = 15) in which mediastinal and residual CPB blood was collected and processed by a continuous autotransfusion system before re-infusion. Intravascular fibrin degradation as indicated by D-dimer generation was measured at five specific intervals and corrected for hemodilution. In addition, chest tube drainage and need for homologous blood were monitored. D-dimer generation increased significantly during CPB in group A, from 312 to 633 vs. 291 to 356 ng/mL in group B (p = .001). The unprocessed residual blood (group A) revealed an unequivocal D-dimer elevation, 4131 ± 1063 vs. 279 ± 103 ng/mL for the processed residual in group B (p < .001). Consequently, in the first post-CPB period, the intravascular fibrin degradation was significantly elevated in group A compared with group B (p = .001). Twenty hours postoperatively, no significant difference in D-dimer levels was detected between both groups. However, a significant intra-group D-dimer elevation pre- vs. postoperative was noticed from 312 to 828 ng/mL in group A and from 291 to 588 ng/mL in group B (p < .01 for both). Postoperative chest tube drainage was higher in the patients from group A, which also had the highest postoperative D-dimer levels. Patients in group A perceived a higher need for transfusions of red cells suspensions post-operatively. These data clearly indicate that autotransfusion management during and after CPB suppresses early postoperative fibrin degradation.
40
Mortada, M. A., R. Hassan y Y. A. Amer. "POS1276 LONG TERM OUTCOME OF MULTIPLE ULTRASOUND GUIDED SUPRASCAPULAR NERVE BLOCK IN TREATMENT OF FROZEN SHOULDER IN DIABETIC PATIENTS". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de mayo de 2021): 922.2–922. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2951.
Texto completoResumen
Background:Frozen shoulder is prevalent among diabetic patients, and usually has aggressive course, with more tendency to be bilateral and resistant to treatment. Suprascapular nerve block (SSNB) is used with increasing frequency by anesthetists and rheumatologists in the management of frozen shoulder. We previously introduced a protocol of nine injections for SSNB with better short term outcome than single SSNB injection (1). Long term outcome of SSNB in management of frozen shoulder is still not detected.Objectives:To evaluate the long term effect of multiple (nine) ultrasound guided supra-scapular nerve block in treatment of diabetic frozen shoulder.Methods:A retrospective cohort study followed up 40 diabetic patients who received a course of ultrasound guided multiple supra-scapular nerve block (9 injections) on 2014. In this study we retrospectively assessed the patients from previously recorded data at a mean duration of 6 years after completing the 9 injection course SSNB clinically by measuring the shoulder active range of motion (using a goniometer in three planes: abduction, internal, and external rotation). Visual analogue scale and Functional assessment by shoulder pain and disability index (SPADI).Results:Thirty four patients (85% of original cohort) completed the long term follow up.The patients were 19 (55.9%) females, 60.6 y mean age, and the mean of disease duration was 85.6 months. The majority of patients (33 patients 97.05%) continues improvement and gained within normal complete range of motions in all directions and excellent grades of shoulder function (Table 1).Table 1.Clinical ParametersAt base lineAt 4 monthsLast follow up at (72months±4)**P valueSPADI pain score (100)(68.8 ± 0.5)a(10.3 ± 7.4)b(0.9±1.9)c0.00*SPADI disability score (100)(69.2 ± 7.7)a(6.25 ± 2.25)b(0.4±0.8)c0.00*SPADI total (100)(69.1 ± 8.5)a(8.15 ± 5.4)b(1.1±0.9)c0.00*Patient global assessment (100)(90.2 ± 8.2)a(8.2 ± 4.2)b(0.4±2.1)c0.00*Night pain (100)(55.4±10.2)a(10.3 ± 4.9)b(2.3±1.1)c0.00*Abduction (180°)(77.5 ± 4.7)a(170.3 ± 10.3)b(174.2±6.2)b0.00*External rotation (100 °)(46 ± 12.6)a(80.1 ± 10.2)b(86.4±10.3)b0.00*Internal rotation (70 °)(34.5 ± 2.4)a(55.4 ± 10.1)b(60.2±9.5)b0.00** P <0.05 there was a statistical significant difference•A,b,c--- the alphabet of different symbols ---means a significant statistical difference between groupsSPADI: shoulder pain and disability indexConclusion:The multiple injection courses for supra-scapular nerve block has an excellent long term efficacy as treatment of diabetic frozen shoulder. This method should be the treatment of choice in patients of diabetic frozen shoulder who do not respond to physiotherapy.References:[1]Mortada, M. A., Ezzeldin, N., Abbas, S. F., Ammar, H. A. & Salama, N. A. Multiple versus single ultrasound guided suprascapular nerve block in treatment of frozen shoulder in diabetic patients. J. Back Musculoskelet. Rehabil. 30, 537–542 (2017).Disclosure of Interests:None declared
41
Bracciale, L., M. Fabbiani, A. Sansoni, L. Luzzi, L. Bernini y G. Zanelli. "Impact of Hepatitis B Vaccination in Children Born to HBsAg-Positive Mothers: a 20-year Retrospective Study". Infection 37, n.º 4 (23 de julio de 2009): 340–43. http://dx.doi.org/10.1007/s15010-008-8252-3.
Texto completo
42
Мачнев, Дмитрий Александрович, Игорь Владимирович Нечаев, Александр Викторович Введенский y Олег Александрович Козадеров. "Квантово-химическое моделирование эндофуллеренов металлов подгруппы скандия". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 22, n.º 3 (23 de septiembre de 2020): 360–72. http://dx.doi.org/10.17308/kcmf.2020.22/2997.
Texto completoResumen
Эндофуллерены, содержащие один или несколько атомов металла внутри углеродного каркаса (металлофуллерены), представляют большой практический интерес в связи с возможностью создания на их основе эффективных контрастирующих агентов для магнитно-резонансной томографии (МРТ), антиоксидантных и противораковых средств. Данные соединения могут быть также использованы в спинтронике для создания наноразмерных электронных устройств. В настоящей работе в рамках теории функционала плотности произведен расчет структурных, электронных и термодинамических характеристик эндофуллеренов металлов подгруппы скандия с числом инкапсулированных атомов от одного до семи в газовой фазе. Описаны стабильные структуры с симметриямиCs, C2, C3 и Ci, соответствующие позициям, занимаемым атомами металла внутри каркаса фуллерена. Установлен теоретический предел числа атомов металла, при котором структура эндофуллерена сохраняет устойчивость – шесть атомов для скандия, четыре для иттрия и три для лантана. Расчет показывает, что наиболее устойчивыми являются структуры с двумя и тремя инкапсулированными атомами. Описана зависимость между числом инкапсулированных атомов металла и характером распределения электронной плотности. Общий заряд на инкапсулированном металлическом кластере положителен для соединений Me@C60 – Me3@C60, слабо положителен для Me4@C60(отдельные атомы имеют отрицательный заряд) и отрицателен для соединений Me5C60 – Me6@C60. Описан эффект спиновой утечки для структур с основным дублетным спиновым состоянием. Для соединений с тремя и более инкапсулированными атомами данный эффект незначителен, что указывает на нецелесообразность создания контрастирующих агентов для МРТ на их основе.
ЛИТЕРАТУРА
1. Kroto H. W., Heath J. R., O’Brien S. C., Curl R. F., Smalley R. E. C60: Buckminsterfullerene. Nature.1985;318(6042): 162–163. DOI: https://doi.org/10.1038/318162a02. Kratschmer W., Lamb L. D., Fostiropoulos K., Huffman D. R. Solid C60: a new form of carbon. Nature.1990;347(6291): 354–358. DOI: https://doi.org/10.1038/347354a03. Buchachenko A. L. Compressed atoms. J. Phys. Chem. B. 2001;105(25): 5839–5846. DOI: https://doi.org/10.1021/jp003852u4. Koltover V. K., Bubnov V. P., Estrin Y. I., Lodygina V. P., Davydov R. M., Subramoni M., Manoharan P. T.Spin-transfer complexesofendohedralmetallofullerenes: ENDOR and NMR evidences. Phys. Chem. Chem. Phys. 2003;5(13): 2774–2777. DOI:https://doi.org/10.1039/b302917d5. Raebiger J. W., Bolskar R. D. Improved production and separation processes for gadoliniummetallofullerenes. J. Phys. Chem. C. 2008;112(17): 6605–6612. DOI: https://doi.org/10.1021/jp076437b6. Gaussian 09, Revision D.01. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb,J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino,B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski,J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida,T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven,K. Throssell, J. A. Montgomery, Jr., J. E. Peralta,F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi,J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene,C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox,Gaussian, Inc., Wallingford CT, 2016. Available at: http://gaussian.com/g09citation7. Neese F. The ORCA program system. WIREs Computational Molecular Science. 2012;2(1): 73–78.DOI: https://doi.org/10.1002/wcms.818. Laikov D. N., Ustynyuk Y. A. PRIRODA-04: a quantum-chemical program suite. New possibilitiesin the study of molecular systems with the application of parallel computing. Russian Chemical Bulletin.2005;54(3): 820–826. DOI: https://doi.org/10.1007/s11172-005-0329-x9. Chandrasekharaiah M. S., Gingerich K. A. Chapter 86 Thermodynamic properties of gaseousspecies. In: Handbook on the Physics and Chemistry of Rare Earths. 1989;12: 409–431. DOI: https://doi.org/10.1016/s0168-1273(89)12010-810. Kohl F. J., Stearns C. A. Vaporization thermodynamics of yttrium dicarbide–carbon systemand dissociation energy of yttrium dicarbide and tetracarbide. J. Chem. Phys., 1970;52(12): 6310–6315.DOI: https://doi.org/10.1063/1.167294211. Gingerich K. A., Nappi B. N., Pelino M., Haque R. Stability of complex dilanthanum carbide molecules.Inorganica Chimica Acta. 1981;54: L141–L142. DOI: https://doi.org/10.1016/s0020-1693(00)95414-812. Hedberg K., Hedberg L., Bethune D. S., Brown C. A., Dorn H. C., Johnson R. D., de Vries M. S.Bond lengths in free molecules of buckminsterfullerene, C60, from gas-phase electron diffraction.Science. 1991;254(5030): 410–412. DOI: https://doi.org/10.1126/science.254.5030.41013. Bethune D. S., Meijer G., Tang W. C., Rosen H. J., Golden W. G., Seki H., Brown C. F., de Vries M. S.Vibrational Raman and infrared spectra of chromatographically separated C60 and C70 fullereneclusters Chem. Phys. Lett., 1991; 179(1–2): 181–186.DOI: https://doi.org/10.1016/0009-2614(91)90312-w14. Эмсли Дж. Элементы. М.: Мир; 1993. 256 c.15. Раков Э. Г. Нанотрубки и фуллерены. Учебн. пособие. М.: Логос; 2006. 376 с.16. Елецкий А. В., Смирнов В. М. Фуллерены. Успехи физических наук.1993;2: 33–60. Режим доступа: https://ufn.ru/ru/articles/1993/2/b/
43
Ramesh, R., A. Inam, D. M. Hwang, T. S. Ravi, T. Sands, X. X. Xi, X. D. Wu, Q. Li, T. Venkatesan y R. Kilaas. "The atomic structure of growth interfaces in Y–Ba–Cu–O thin films". Journal of Materials Research 6, n.º 11 (noviembre de 1991): 2264–71. http://dx.doi.org/10.1557/jmr.1991.2264.
Texto completoResumen
We have examined the atomic structure of growth interfaces in thin films of Y–Ba–Cu–O grown on [001] perovskite or cubic substrates. At substrate heater temperatures in the range of 780–820 °C c-axis oriented growth is observed on these substrates. On SrTiO3, the first layer appears to be either a BaO or a CuO2 plane while on LaAlO3 the first layer appears to be a CuO chain layer. The mismatch on the a-b plane is accommodated by the formation of interface dislocations. Defects on the substrate surface propagate as defects in the film. These defects are primarily translational boundaries and in some cases second phases. At lower substrate heater temperatures, i.e., 650–700 °C, a, b-axis growth dominates. Defects and steps on the substrate surface are more detrimental in the growth of a, b-axis oriented films, since they tend to favor the nucleation of c-axis oriented domains. This is ascribed to the ledge mechanism of c-axis film growth, for which the surface steps are good nucleation sites.
44
Kwak, Jae-Yong, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim y Yong-Geun Kwak. "The Comparative Analysis of Serum Proteomes for the Discovery of Biomarkers for Essential Thrombocythemia." Blood 106, n.º 11 (16 de noviembre de 2005): 4004. http://dx.doi.org/10.1182/blood.v106.11.4004.4004.
Texto completoResumen
Abstract Background: Essential thrombocythemia(ET) is a clonal disorder involving a hematopoietic progenitor cell and is manifested by the overproduction of platelets. There is as yet no pathognomonic diagnostic test. In our study, to identify the biomarkers for an initial diagnosis by a lesser invasive method, serum proteins reflecting alteration their proteomes were analysed. Methods: We compared two-dimensional electrophoresis patterns of human sera of twelve patients with ET with that of normal twelve subjects. The differentially expressed spots were identified by matrix-assisted laser desorption/ionization-time-of flight(MALDI-TOF) and electrospray ionization quadupole time of flight(ESI-Q-TOF)mass spectrometry. Results: Twenty two spots that expressed differentially in ET group were found. The expression levels of fibrinogen γ, fibrinogen γ-A chain precursor, ALB protein, α-2 macroglobulin, H factor-1, α-2-macroglobulin precursor, ceruloplasmin, α-1-B-glycoprotein, α-2-plasmin inhibitor, α-1-B-glycoprotein and an unknown protein were up-regulated in serum of ET patients, whereas the other proteins including complement fator B preproprotein, afamin precursor, inter-α inhibitor H4, immunoglobulin heavy chain constant region γ 1, immunoglobulin κ light chain and an unknown protein down-regulated. Conclusion: These results suggest that these proteins can be used as less invasive diagnostic and follow-up biomarkers of ET if further studies were done. The proteins significantly changed in sera of ET Spot no. Name Accession no. % coverage Mw(KDa)/pI(Measured) Mw(KDa)/pI(database) ET(%) 67 fibrinogen γ 223170 39 50.57/5.6 46.82/5.5 2.54±0.52 69 ” 223170 33 50.57/5.6 46.83/5.5 3.93±1.19 73 fibrinogen γ-A chain precursor 71827 23 48.93/5.6 50.11/5.7 3.89±0.98 74 ” 71827 22 48.93/5.8 50.11/5.7 3.10±0.91 77 ALB protein 27692693 21 50.57/5.9 48.65/6.0 3.77±0.58 89 α-2-macroglobulin 177872 14 263.89/6.1 71.35/5.5 1.95±0.32 100 H factor 1 4504875 20 248.95/5.7 143.79/6.3 5.8±1.78 112 α-2-macroglobulin precursor 4557225 9 151.38/5.7 164.69/6.0 2.18±0.38 125 complement factor B preproprotein 4502397 14 151.38/5.7 86.86/6.6 0.49±0.07 138 afamin precursor 4501987 12 65.01/5.1 85.53/6.3 0.31±0.07 139 ” 4501987 12 65.01/5.1 85.53/6.3 0.36±0.09 140 inter- α inhibitor H4 31542984 12 93.33/5.3 103.57/6.5 0.36±0.08 154 ceruloplasmin 4557485 8 132.89/5.3 123.04/5.4 3.34±0.80 161 α-1-B-glycoprotein 69990 21 84.50/5.0 52.49/5.6 4.23±0.98 162 α-2-plasmin inhibitor 11386143 14 78.58/5.0 54.92/5.8 1.95±0.38 167 α-1-B-glycoprotein 69990 28 80.87/5.3 52.49/5.6 1.73±0.04 210 Not identified - - 38.47/4.6 - 2.77±0.20 249 immunoglobulin heavy chain constant regionγ 1 12054072 15 39.021/8.1 36.65/8.8 0.40±0.09 250 ” 12054072 18 38.79/8.2 36.65/8.8 0.34±0.14 252 ” 12054072 19 38.50/8.3 36.65/8.8 0.37±0.09 262 unknown 15679996 36 24.73/8.2 23.32/8.6 0.30±0.13 265 immunoglobulinκ light chain 2765423 22 25.75/8.8 25.93/9.2 0.28±0.12 Figure Figure
45
O’Brien, Susan M., Hagop Kantarjian, Deborah A. Thomas, Francis J. Giles, Emil J. Freireich, Jorge Cortes, Susan Lerner y Michael J. Keating. "Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia". Journal of Clinical Oncology 19, n.º 8 (15 de abril de 2001): 2165–70. http://dx.doi.org/10.1200/jco.2001.19.8.2165.
Texto completoResumen
PURPOSE: To conduct a dose-escalation trial of rituximab in patients with chronic lymphocytic leukemia (CLL) to define the maximum-tolerated dose (MTD), to evaluate first-dose reactions in patients with high circulating lymphocyte counts, and to assess the efficacy at higher versus lower doses. PATIENTS AND METHODS: Fifty patients with CLL (n = 40) or other mature B-cell lymphoid leukemias (n = 10) were treated with four weekly infusions of rituximab. The first dose was 375 mg/m2 for all patients; dose- escalation began with dose 2 but was held constant for each patient. Escalated doses were from 500 to 2,250 mg/m2. RESULTS: Toxicity with the first dose (375 mg/m2) was noted in 94% of patients but was grade 1 or 2 in most, predominantly fever and chills. Six patients (12%) experienced severe toxicity with the first dose, including fever, chills, dyspnea, and hypoxia in all six patients, hypotension in five, and hypertension in one. Toxicity on subsequent doses was minimal until a dose of 2,250 mg/m2 was achieved. Eight (67%) of 12 patients had grade 2 toxicity, including fever, chills, nausea, and malaise, although no patient had grade 3 or 4 toxicity. Severe toxicity with the first dose was significantly more common in patients with other B-cell leukemias, occurring in five (50%) of 10 patients versus one (2%) of 40 patients with CLL (P < .001). The overall response rate was 40%; all responses in patients with CLL were partial remissions. Response rates were 36% in CLL and 60% in other B-cell lymphoid leukemias. Response was correlated with dose: 22% for patients treated at 500 to 825 mg/m2, 43% for those treated at 1,000 to 1,500 mg/m2, and 75% for those treated at the highest dose of 2,250 mg/m2 (P = .007). The median time to disease progression was 8 months. Myelosuppression and infections were uncommon. CONCLUSION: Rituximab has significant activity in patients with CLL at the higher dose levels. Severe first-dose reactions were uncommon in patients with CLL, even with high circulating lymphocyte counts, but were frequent in patients with other mature B-cell leukemias in which CD20 surface expression is increased. Efficacy of rituximab was also significant in this group of patients.
46
Blake, R. W., R. Kolotylo y H. de la Cueva. "Flight speeds of the barn swallow, Hirundo rustica". Canadian Journal of Zoology 68, n.º 1 (1 de enero de 1990): 1–5. http://dx.doi.org/10.1139/z90-001.
Texto completoResumen
A Doppler radar hand gun was used to measure flight speeds of barn swallows (Hirundo rustica) to determine whether mean flight speed coincides with either the minimum power, Vmp, or maximum range, Vmr, speeds predicted by aerodynamic theory. In addition, flight speeds are also compared with the maximum range speed, V′mr, when the mechanical equivalent of the standard metabolic rate is included in the power curve. A total of 821 speed recordings were divided into two groups based on observed flight behaviour. Group A had characteristically low (<0.5 m above the ground) and straight flight paths. Group B flew higher (>0.5 m) and erratically. Mean flight speeds of 8.6 and 6.8 m∙s−1 were determined for groups A and B, respectively. When compared separately, both means are significantly different from predicted values of Vmp (= 4.2 m∙s−1, p < 0.001), Vmr (= 5.6 m∙s−1, p < 0.001), and V′mr (= 6.2 m∙s−1, p < 0.001). It is likely that the birds fly at significantly higher speeds than the predicted optima for most routine flight activities. The penalties involved in departing from Vmp, Vmr, and V′mr (assessed as percent increase in total aerodynamic power relative to Vmp, Vmr, or V′mr) are substantial.
47
Massa, Alicia N. y Craig F. Morris. "Molecular Evolution of the Puroindoline-a, Puroindoline-b, and Grain Softness Protein-1 Genes in the Tribe Triticeae". Journal of Molecular Evolution 63, n.º 5 (noviembre de 2006): 718. http://dx.doi.org/10.1007/s00239-006-8292-1.
Texto completo
48
Naik, Mude Bhaskar, Vinayak S. Sirsat, Shailendra Chauhan y Deepak M. Kokane. "A Comparison of Analgesic Effect of Different Doses of Intrathecal Nalbuphine Hydrocloride with Bupivacaine and Bupivacaine alone for Lower Abdominal and Orthopedic Surgeries". Indian Journal of Anesthesia and Analgesia 9, n.º 1 (15 de febrero de 2022): 15–19. http://dx.doi.org/10.21088/ijaa.2349.8471.9122.2.
Texto completoResumen
Objective: To compare the analgesic effect of different doses of nalbuphine when added to bupivacaine in spinal anaesthesia. To compare the onset of sensory blockade (time taken form 3, 5 min and then every 5 min until the end of the procedure. Methods: 100 ASA grade 1 and 2 patients grouped into group A, group B, group C and group D randomly. Age group of 18-60 years. Patient undergoing elective lower abdominal and orthopedic surgery received with Group A : included 25patients with 0.5% hyperbaric bupivacaine 3 cc (15mg) + N.S. 0.2 ml. Group B: included 25 patients with 0.5% hyperbaric bupivacaine (3 cc) 15 mg + 0.8mg nalbuphine + N.S. 0.2 ml. Group C: included 25 patients with 0.5% hyperbaric bupivacaine (3 cc) 15 mg + 1.6mg nalbuphine + N.S. 0.2 ml. Group D: included 25 patients with 0.5% hyperbaric bupivacaine (3 cc) 15 mg + 2.4 mg nalbuphine + N.S. 0.2 ml. Results: The mean sensory onset of study subjects in group A, B, C and D were 8.4±0.5, 5±0.9, 5.6±1 and 8.2±1.4 respectively and this difference was statistically significant. The mean motor onset of study subjects in group A, B, C and D were 10.2±0.7, 6.8±0.9, 6.1±1.2 and 8.6±1.1 respectively and this difference was statistically significant. The mean sensory duration of study subjects in group A, B, C and D were 176.8±29.3, 282±6.8, 300.2±6.6 and 286.2±9.8 respectively and this difference was statistically significant. The mean time for maximum sensory level of study subjects in group A, B, C and D were 11.5±1, 8.8±0.8, 5.6±1.6 and 8.2±1.2 respectively and this difference was statistically significant. The mean T 10 time of study subjects in group A, B, C and D were 8.5±0.5, 8.7±0.7, 5.6±1.6 and 8.6±1 respectively and this difference was statistically significant. The mean time for 2 segment regression of study subjects in group A, B, C and D were 76.6±2, 92.2±2.3, 95.8±3 and 90.6±4.4 respectively and this difference was statistically significant. The mean motor duration of study subjects in group A, B, C and D were 179.8±8.9, 184.6±6, 203.2±7 and 187±9.9 respectively and this difference was statistically significant. The mean analgesic duration of study subjects in group A, B, C and D were 175.8±4.1, 271.1±7.8, 303.8±9.9 and 279±10.7 respectively and this difference was statistically significant. Conclusion: We came to conclusion that 0.5% hyperbaric bupivacaine (15mg) with nalbuphine (0.8mg, 1.6 mg, 2.4 mg) in subarachnoid block. Therefore addition of 1.6 mg nalbuphine to 15mg of 0.5% hyperbaric bupivacaine 15 mg in subarachnoid block can be considered safe with minimum complication, and provides excellent quality and longer duration of postoperative analgesia with good sedation compared with 0.8 mg and 2.4 of nalbuphine. So it is useful for prolonged duration of postoperative analgesia.
49
Cai, Qingqing, Kailin Chen, Qirong Geng, Guangzheng Zhong, Jianping Li, Huiqiang Huang, Tongyu Lin, Wenqi Jiang y Zhiming Li. "Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma". Blood 124, n.º 21 (6 de diciembre de 2014): 1655. http://dx.doi.org/10.1182/blood.v124.21.1655.1655.
Texto completoResumen
Abstract Background: With antivirus prophylaxis, reactivation of hepatitis B virus (HBV) also occurred in HBV carriers (hepatitis B surface antigen [HBsAg] positive) undergoing rituximab combination chemotherapy. It was reported that most HBV carriers with improved long-term outcomes were seropositive for hepatitis B e antibody (HBeAb). In this study on HBsAg-positive lymphoma patients with prophylaxis, the objectives were to determine the HBV reactivation rate in patients with HBeAb positive compared with the patients with HBeAb negative. Methods: We retrospectively analyzed the medical records of 113 HBV carriers with CD20(+) diffuse large B-cell lymphoma (DLBCL) received R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy with antivirus prophylaxis between August 1, 2002 and November 31, 2011 at Sun Yat-sen University Cancer Center, China. Results: Among 113 HBV carriers with CD20(+) DLBCL, 68(60.2%) were hepatitis B e antibody (HBeAb) positive. There was no significant difference in terms of sex distribution, age, ECOG PS, stage, baseline HBV DNA detectable rate, or ALT, AST, bilirubin, or LDH between the HBeAb positive group and the HBeAb negative group. However, there were a significantly higher proportion of HBeAg seronegativity (94.1%v 24.4%; P< .001), and HBcAb seropositivity (100.0%v 82.2%; P< .001) in the HBeAb positive group. All the patients received antiviral therapy before chemotherapy. The antiviral treatments were used as follows: lamivudine in 68 (60.2%) patients, entecavir in 18 (15.2%) patients, others in 27 (23.8%) patients. Other antiviral treatments were including adefovir, lamivudine plus entecavir, lamivudine at beginning and then entecavir, and so on. No significant difference was observed in the antiviral drugs between the two groups. After R-CHOP chemotherapy, HBV reactivation was found in 23.0% of HBV carriers (26/113). And its incidence rate was lower in HBsAg- positive / HBeAb positive patients than in HBsAg-positive/ HBeAb negative patients (16.1% versus 33.3%; P =.034). Multivariate analysis showed that patients positive for HBeAb before chemotherapy was the only significant and independent protective factor associated with hepatitis due to HBV reactivation after chemotherapy. Chemotherapy was continued when the serum HBV-DNA level reduced or liver function improved. Survival was not affected by the occurrence of HBV reactivation or the status of HBeAb. Conclusion: HBeAb positive before rituximab combination chemotherapy was associated with a lower risk of HBV reactivation in HBV carriers with CD20(+) DLBCL. A more effective antivirus prophylaxis may be considered in HBV carriers with HBeAb negative in order to reduce HBV reactivation. Disclosures No relevant conflicts of interest to declare.
50
Hussain, Hamid, Zhang Shuangxi, Muhammad Usman y Muhammad Abid. "Spatial Variation of b-Values and Their Relationship with the Fault Blocks in the Western Part of the Tibetan Plateau and Its Surrounding Areas". Entropy 22, n.º 9 (11 de septiembre de 2020): 1016. http://dx.doi.org/10.3390/e22091016.
Texto completoResumen
The Tibetan Plateau is considered to be one of the best natural laboratories for seismological research. This study sought to determine the spatial variations of b-values in the western part of the Tibetan Plateau, along with its surrounding areas, and the relation with the region’s fault blocks. The study region lies within 27–36.5° N, 78–89° E, and its fracture structure consists of strike-slip faults, as well as normal and thrust faults. A catalog record from 2009–2019 provided 4431 well-centered earthquakes that varied in magnitude from 0.1 to 8.2 M. The record was obtained from China’s seismological network, which is capable of recording low magnitudes to analyze b-values in the study area. The key findings of this study are as follows: (1) the range of earthquake depth in the region was 0–256 km, with the depth histogram showing a high frequency occurrence of shallow earthquakes in the area; (2) a time histogram showed that the major earthquakes occurred between 2014–2015, including the notable 2015 Gorkha earthquake (M = 8.2); (3) the b-value computed in the study area was 0.5 to 1.6, but in most of the study area, the b-value ranged from 0.6 to 0.9, which was a low to intermediate value, due to the presence of strike-slip faults in the central part of the study area and underthrusting in the region (south of the study area); and (4) a high b-value was found in the northwestern and eastern regions of the area, which proved that the area is prone to small earthquakes in the near future. The study also showed that the central and southern areas of the study region had low to intermediate b-values, meaning that it is prone to destructive and massive earthquakes with high magnitudes, such as the Gorkha earthquake (southern part of the study area). Low b-values revealed the degree of variation in rock properties, including large stress and strain, a fractured medium, a high deformation rate, and large faults. Small b-values were observed when the stress level was high in the investigated region, which might be used to predict a massive high-magnitude earthquake in the near future.